UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

FOR THE FISCAL YEAR ENDED March 31, ~~2022~~2023

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

COMMISSION FILE NUMBER: 000-5627

Dr. Foods, Inc.

(Exact name of registrant as specified in its charter)

	Nevada	00-0000000
	(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

	3F K’s Minamiaoyama 6-6-20 Minamiaoyama, Minato-ku, Tokyo 107-0062, Japan	107-0062
	(Address of Principal Executive Offices)	(Zip Code)

Securities to be registered under Section 12(b) of the Act: None

Securities to be registered under Section 12(g) of the Exchange Act:

	Title of each class		Name of each exchange on which registered
	Common Stock, $.0001		N/A
	Common Stock, $0.0001		N/A

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

[ ] Yes [X] No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

[ ] Yes [X] No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[X ] Yes [ X] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

[X ] Yes [ X] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

[ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐		Accelerated filer ☐		Non-accelerated filer ☒
Smaller reporting company ☒		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[ ] Yes [X] No

As of September 30, ~~2021~~2022, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting common stock held by non-affiliates of the ~~Registrant~~registrant ~~(without~~was ~~admitting~~approximately ~~that~~$6,367,034 ~~any~~based ~~person~~on ~~whose~~the ~~shares~~closing ~~are~~price per share (or ~~not~~$0.55), ~~included~~of inthe ~~such~~registrant’s ~~calculation~~common isstock anas ~~affiliate)~~reported ~~was~~by ~~approximately~~OTC ~~$90,295,786~~Markets Group Inc.

As of ~~June~~August 1316, ~~2022~~2023, there were 213,~~622~~708,~~968,890 shares~~699 shares of the Registrant's ~~common~~Common ~~stock~~Stock, par value $0.0001 per share, and 10,000 shares of the Registrant’s ~~preferred~~Series ~~stock,~~Z Preferred Stock, par value $0.0001 per share, issued and outstanding.

- 1 -

Table of Contents

TABLE OF CONTENTS

Dr. Foods, INC.

PART I		PAGE
Item 1	Business	3
Item 1A	Risk Factors	6
Item 1B	Unresolved Staff Comments	6
Item 2	Properties	6
Item 3	Legal Proceedings	6
Item 4	Mine Safety Disclosures	6
PART II
Item 5	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	7
Item 6	Selected Financial Data	8
Item 7	Management's Discussion and Analysis of Financial Condition and Results of Operations	8
Item 7A	Quantitative and Qualitative Disclosures about Market Risk	8
Item 8	Financial Statements and Supplementary Data	F1-F8F9
Item 9	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	9
Item 9A	Controls and Procedures	9
Item 9B	Other Information	9
PART III
Item 10	Directors, Executive Officers and Corporate Governance	10
Item 11	Executive Compensation	11
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	12
Item 13	Certain Relationships and Related Transactions, and Director Independence	12
Item 14	Principal Accounting Fees and Services	12
PART IV
Item 15	Exhibits, Financial Statement Schedules	13
	Signatures	13

- 2 -

Table of Contents

PART I

Item 1. Business

Corporate History

Dr. Foods, Inc. (we, us, our, the "Company" or the "Registrant"), formerly known as Catapult Solutions, Inc., was incorporated in the State of Nevada on February 26, 2021.

On February 26, 2021, Jeffrey DeNunzio was appointed Chief Executive Officer, Chief Financial Officer, and Director of Catapult Solutions, Inc.

The Company ~~was~~ was created for the sole purpose of participating in a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250. The constituent corporations in the Reorganization were Ambient Water Corporation (“AWGI” or “Predecessor”), Catapult Solutions, Inc. (“Successor”), and Catapult Merger Sub, Inc. (“Merger Sub”). Our ~~director~~now isformer director, ~~and~~Jeffrey ~~was~~DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization, ~~anticipated~~which ~~Reorganization~~is described below.

Catapult Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Catapult Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Catapult Solutions, Inc. became a wholly owned direct subsidiary of Ambient Water Corporation and Merger Sub became a wholly owned and direct subsidiary of Catapult Solutions, Inc.

Pursuant to the above, on April 23, 2021, Ambient Water Corporation filed Articles of Merger with the Nevada Secretary of State. The merger became effective on April 28, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Catapult Solutions, Inc.’s common stock. At the time of the merger, 10,000 shares of Series Z Preferred Stock were issued to CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, for services rendered to the Company. Series Z Preferred Stock has no conversion rights to any other class, and every vote of Series Z Preferred Stock has voting rights equal to 1,000,000 votes of Common Stock.

On July 20, 2021, the Company entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a ~~Wyoming~~ Wyoming Limited Liability Company (“CRS”), White Knight Co., Ltd., a Japan Company (“WKC”), and Next Meats Holdings, Inc., a Nevada Company (“NXMH”), pursuant to which, on July 23, 2021, (“Closing Date”), CRS sold 10,000 shares of the Company’s Series Z Preferred Stock, representing, at the time, approximately 81.20% voting control of the Company; 5,000 shares of Series Z Preferred Stock were transferred to WKC and 5,000 shares of Series Z Preferred Stock were transferred to NXMH. WKC and NXMH paid consideration of three hundred seventy-five thousand dollars ($375,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with WKC and NXMH, becoming the Company’s largest controlling stockholders at the time of the transaction.

On the Closing Date, July 23, 2021, Mr. Jeffrey DeNunzio resigned as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer and Director. On the Closing Date, Mr. Koichi Ishizuka was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.

On August 24, 2021, the Company changed its name with the Nevada Secretary of State to Dr. Foods, Inc.

On or about September 17, 2021, we incorporated Dr. Foods Co., Ltd., a Japan Company, as a wholly owned subsidiary of the Company. We intend to utilize Dr. Foods Co., Ltd. to, amongst other things, act as an importer, reseller, developer, and manufacturer of various food products that we may develop in the future.

At this time, our wholly subsidiary, Dr. Foods Co., Ltd. has three officers, Koichi Ishizuka, Chief Executive Officer, and two Executive Officers, Iaroslav Patuk and Hideo Fujioka.

On October 11, 2021, we, through our wholly owned subsidiary Dr. Foods Co., Ltd., entered into and consummated a “Collaboration Agreement” with Next Meats Co., Ltd., a Japan company that shares common management with the Company, to co-develop new food products and subsequently offer them for sale. Next Meats Co., Ltd. operates in the “alternative meat” industry. It currently offers, and plans to continue to offer, amongst other things, artificial chicken and beef products made from meat substitutes.

The ~~Collaboration~~ Collaboration Agreement is for a period of two years and may be renewed thereafter under the same terms for additional one year terms unless terminated in writing, with three months’ notice, by either party. The Collaboration Agreement, amongst other things, details the terms and conditions by which Next Meats Co., Ltd. and Dr. Foods Co., Ltd. may co-develop, cooperate and contribute towards the development of new products and technologies. The specific allotment of tasks per project ~~will~~was besupposed to be determined in writing by each party at the outset of collaborative efforts. To date, no specific details have been committed to writing, despite the fact that collaborative efforts have begun. It has been verbally determined that Dr. Foods Co., Ltd. will primarily, although not exclusively, contribute to research and development, and Next Meats Co., Ltd. will primarily, although not exclusively, contribute to distribution of new products/technologies. Costs pursuant to the collaborative efforts of the partners are, ~~will~~anticipated to be, the respective responsibility of the party responsible for fulfilling such tasks.

Dr. Foods Co., Ltd. intends to conduct research and development of new food products pursuant to the Collaboration Agreement via its three new executive officers, all of whom were appointed on October 11th of 2021.

On November 3, 2021, we began trading under the symbol DRFS. The new CUSIP number associated with our common stock, as of the market effective date of November 3, 2021, is 26140D107.

On January 12, 2022, Dr. Foods, Inc., a Nevada Company, Mama Foods Co., Ltd., a Japan Company, and White Knight Co., Ltd., a Japan Company entered ~~into~~ into a non-definitive agreement, a “Letter of Intent”, whereas it iswas proposed that Dr. Foods, Inc., will acquire 100% of the controlling interest of Mama Foods Co., Ltd. from White Knight Co., Ltd. in exchange for $500,000 coupled with the issuance of 19,500,000 shares of restricted Preferred Stock to White Knight Co., Ltd. The issuance of shares shall be subject to the rules and limitations set forth by the Securities Act Rule 144.

White Knight Co., Ltd. is a Japanese entity owned and controlled by Koichi Ishizuka.

- 3 -

Table of Contents

Mama Foods, Co., Ltd. (“Mama Foods”) is a food company founded in Japan in 1958, currently offering customers in Japan wholesale and retail products centering on Japanese side dishes, from chilled foods to packed and sterilized food. Mama Foods uses ingredients carefully taken from natural kelp and bonito without adding any chemical seasonings, preservatives, coloring agents, etc. Mama Foods has two existing “in house” production facilities and produces 100% of its current product offerings. From time to time, it also produces products of other third parties, including certain products offered for sale by Next Meats Co., Ltd., such as “Next Kalbi 2.0”, a boneless short rib made from meat substitutes. Currently, Mama Foods employs approximately 4344 individuals. In 2021, White Knight Co., Ltd. acquired 100% of Mama Foods from its prior controller, in exchange for approximately 1 million USD. The current website for Mama Foods, which includes additional information, can be found here: mama-foods.com/en/

On March 31, 2022, Dr. Foods, Inc. and Mama Foods mutually agreed to extend the terms of the non-definitive agreement 30 more days in order to provide more time to prepare the books and records of Mama Foods Co., Ltd. ~~There~~This isextension noperiod ~~guarantee~~had ~~that~~expired ~~this~~without ~~will~~the bebooks ~~sufficient~~and ~~time~~records toof ~~complete~~Mama ~~the~~Foods Co., ~~transaction(s)~~Ltd. ~~contemplated~~having been prepared or progressed in ~~the~~any ~~non-definitive~~meaningful ~~agreement~~capacity. IfOn ~~agreed~~May ~~upon~~6, ~~all~~2022 the parties ~~may~~again ~~elect~~agreed to ~~further~~ extend the terms of the ~~Letter~~non-definitive agreement, however this time with an expiration date of ~~Intent~~June 30, 2022, or until, if agreed upon by all parties, further notice.

~~Our~~On ~~majority~~June ~~shareholders~~30, ~~collectively,~~ ~~White Knight Co.~~2022, ~~Ltd.~~the ~~and~~non-definitive ~~Next~~agreement ~~Meats~~terminated ~~Holdings,~~without ~~Inc.,~~the books and ~~our~~records ~~Board~~ of ~~Directors,~~Mama ~~have~~Foods ~~executed~~Co., aLtd. ~~resolution~~having tobeen ~~ratify, affirm,~~prepared ~~and~~or ~~approve~~progressed ~~an amendment~~ to ~~our~~the ~~Certificate~~satisfaction of ~~Incorporation,~~the ~~increasing~~Issuer. ~~the~~Upon ~~authorized~~termination, ~~shares~~common management of ~~our~~both ~~Common~~Mama ~~Stock~~Foods ~~from 2~~Co.,~~400,000,000~~ toLtd. ~~4,800,000,000~~and Dr. ~~The~~Foods, ~~Amendment~~Inc. ~~was~~verbally ~~filed~~agreed ~~with~~to extend the ~~Nevada~~letter ~~Secretary~~ of ~~State~~intent onindefinitely ~~February~~until ~~22,~~further ~~2022, effective immediately upon filing~~notice.

~~On or~~The ~~about~~efforts ~~May~~to ~~31,~~spearhead ~~2022~~preparation of the books and records had been, weand ~~sold~~continues ~~307~~to be,~~692,308~~ ~~shares~~led ofby ~~restricted~~Koichi ~~Common~~Ishizuka ~~Stock~~who tohas SJoutside ~~Capital~~business Cointerests and other demands upon his time that limit his availability., ~~Ltd~~It should also be noted that he does not have expertise in accounting matters. As such, athe ~~Japanese~~Company has engaged outside accounting expertise to assist in this process. The Company cannot state, atwith aany ~~price~~level of certainty, when, or if, the books and records will be prepared to the satisfaction of ~~$0.0025~~the ~~USD~~Issuer, ~~per~~and ~~share~~as such, when the books and records of ~~Common~~Mama ~~Stock~~Foods Co., Ltd. will be fully audited by a PCAOB auditor.

~~The~~Currently, ~~proceeds~~the ~~from~~Company ~~this~~is ~~sale~~pending ~~are~~moving toforward bewith ~~used~~the byacquisition of Mama Foods Co., Ltd. due to the ~~Company~~fact that Mama Foods Co., Ltd. requires, and has yet to complete, a PCAOB audit of its financial statements for ~~working~~the ~~capital~~last two fiscal years. At this time, the audit is actively taking place by M&K CPAS, PLLC (“M&K”). However, we understand that progress has been minimal.

The ~~aforementioned~~Company ~~sale~~cannot ofestimate ~~shares~~with ~~was~~any ~~conducted~~level ~~pursuant~~of tocertainty ~~Regulation~~how Slong of the ~~Securities~~aforementioned ~~Act~~audit of ~~1933,~~Mama asFoods ~~amended~~Co., ~~("Regulation S")~~Ltd. ~~The sale~~may oftake ~~shares was made only~~ to ~~non-U~~complete.S. ~~persons/entities~~The ~~(as~~Company ~~defined~~does ~~under~~not ~~Rule~~intend ~~902 section (k)(2)(i) of Regulation S), pursuant~~ to ~~offshore~~ ~~transactions,~~acquire ~~and~~Mama noFoods ~~directed selling efforts were made in the United States by the issuer~~Co., ~~a distributor~~Ltd., under any ~~of their respective affiliates~~terms, orprior ~~any~~to ~~person~~the ~~acting~~completion ~~on behalf~~ of ~~any~~its ~~of the foregoing~~PCAOB audit.

~~Following~~There ~~the~~is ~~sale~~a ofrisk ~~restricted~~that ~~common~~the ~~shares~~audit toof SJMama ~~Capital~~Foods Co., Ltd. is not completed at all, and/or that we ~~now~~never ~~have~~acquire 2Mama Foods Co.,~~622~~ Ltd. Even if the acquisition of Mama Foods Co.,~~968~~ Ltd. is completed,~~890~~ ~~shares~~there is the possibility that the terms of ~~Common~~this ~~Stock~~acquisition, ~~issued~~which ~~and~~is ~~outstanding~~non-definitive asat ofthis time, may not be considered favorable for the ~~date~~company ofand/or ~~this~~its ~~report~~shareholders.

~~The~~In ~~Company’s~~February ~~main~~of 2022, ~~office~~our ismajority ~~located~~shareholders executed a resolution to ratify, affirm, and approve an amendment to our Certificate of Incorporation, atincreasing 3Fthe ~~K’s~~authorized ~~Minamiaoyama 6-6-20~~shares ~~Minamiaoyama~~of our Common Stock from 2,400,000,000 ~~Minato-ku~~to 4,800,000,000. ~~Tokyo~~The ~~107-0062~~Amendment was filed with the Nevada Secretary of State on February 22, ~~Japan~~2022, effective immediately upon filing.

On or about April 7, 2022, the Company’s wholly owned subsidiary, Dr. Foods Co., Ltd., consummated a “Collaborative Research Agreement” (herein referred to as the “CRA”) with the National University Corporation Osaka University. Together with Osaka University, Dr Foods Co., Ltd. plans to research, develop, and take other related measures to evaluate the function of lab-grown meat. Specifically, both parties will endeavor to research the cultivation of animal cells, and evaluate the differences in functionality between livestock meat, lab-grown meat and meat substitutes. The agreement terminates on March 31, 2025. The collaborative efforts are planned to take place at the Matsuzaki Laboratory, located within the Department of Applied Chemistry, at the Graduate School of Engineering - Osaka University. Dr. Foods Co., Ltd. will bear responsibility for any direct expenses related to the CRA, which are estimated to be 2,000,000 Yen (approximately $15,623 at today’s exchange rate). To date, there are no material updates to report regarding this venture as no research efforts have yet to take place.

On or about July 1, 2022, NXMH sold 5,000 shares of Series Z Preferred Stock of DRFS, to WKC, at a price of approximately $147,624 USD (20,000,000 Japanese Yen) (“The Share Purchase Agreement”). WKC is owned and controlled by our Chief Executive Officer, Koichi Ishizuka. WKC is deemed to be an accredited investor. The purchase of shares was made for investment purposes. The consummation of the transaction contemplated by the Share Purchase Agreement resulted in NXMH no longer having an equity position in DRFS and with WKC becoming the largest controlling shareholder of DRFS.

On July 11, 2022, DRFS dismissed its independent registered public accounting firm, BF Borgers CPA PC (“BFG”) effective immediately. This decision was approved by the Company’s Board of Directors, comprised solely of Koichi Ishizuka.

On July 11, 2022, the Company engaged M&K CPAS, PLLC (“M&K”) as its new independent registered public accountant for the fiscal year ending March 31, 2023. This decision was approved by the Company’s Board of Directors, comprised solely of Koichi Ishizuka.

On September 13, 2022, the Company filed a certificate of change (the “certificate”) with the Nevada Secretary of State to effect a reverse stock split (the “stock split”), whereas every 200 shares of the Company’s issued and outstanding common stock would be automatically converted into one issued and outstanding share of common stock, without any change in the par value per share. The effective date of the certificate was September 21, 2022. Fractional shares as a result of the stock split were rounded up to the nearest whole number. The stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the stock split. The authorized shares prior and following the stock split remain the same at 4,800,000,000 shares of common stock, par value $0.0001 per share. Immediately prior to the stock split, we had 2,622,968,890 shares of common stock issued and outstanding. Immediately following the September 21, 2022 effective date of the stock split, we had 13,114,888 shares of common stock issued and outstanding. The effective date listed on the Certificate of September 21, 2022 differs from the Market Effective Date of the Reverse Stock Split, which was on September 28, 2022. The FINRA Daily List Announcement Date was on September 27, 2022. Our new CUSIP number for our shares of Common Stock is 26140D206.

On or about October 17, 2022, we incorporated DR FOODS (S) PTE. LTD., a Singapore Private Company limited by shares. DR FOODS (S) PTE. LTD., which may be referred to herein as, “DRFS Singapore” is now a wholly owned subsidiary of the Company. Currently, and as of April 2023, there is one Officer and Director of DRFS Singapore, which is Mr. Koichi Ishizuka. Any and all previous officers and directors of DRFS Singapore are no longer with DRFS Singapore.

The intended business purpose of DRFS Singapore is primarily, but not limited to, further researching, developing, and, in the future, selling food products in Singapore, some of which may be plant based or cultured meats.

Currently, we operate through Dr. Foods Co., Ltd. and DRFS Singapore and share the same business plan as that of Dr. Foods Co., Ltd. and DRFS Singapore.

At this time, we neither rent nor own any properties. We utilize the office space and equipment of Next Meats Co., Ltd., as well as office space of our management, at no cost. Management estimates such amounts to be immaterial.

The Company has elected March 31st as its year end.

Overview

~~On or about September 17~~Currently, ~~2021,~~ we ~~incorporated Dr.~~operate ~~Foods~~through ~~Co., Ltd., a Japan Company, as a wholly owned subsidiary of the Company. We intend to utilize~~ Dr. Foods Co., Ltd. ~~to, amongst other things, act as an importer, reseller, developer,~~ and ~~manufacturer~~DRFS ofSingapore ~~various food products that we may develop in the future. We now operate exclusively through Dr. Foods Co., Ltd.~~ and share the same business plan as that of Dr. Foods Co., Ltd. and DRFS Singapore.

At present, our principal focus is on the creation of plant-based food products to replace traditional animal products, while retaining the taste and texture of the original.

Our company philosophy is to “save the next generation of ‘food’ through science and technology” through conducting scientific studies of the world’s foods. We believe that plant based foods will not only become increasingly popular over the course of the next century, but that they will also help to solve, or alleviate, many of the problems created by the current meat supply chain. Some, but certainly not all, of the negative environmental effects that have been associated with meat production are pollution through fossil fuel usage, animal methane, effluent waste, and water and land consumption.

At present, our principal focus is on the creation of plant-based food products to replace traditional animal products, while retaining the taste and texture of the original. One of our key objectives is to create microalgae food, which is to say the development of plant-based products using microalgae as a base, in order to support the health of the consumer. Microalgae, or microphytes, are microscopic algae invisible to the naked eye. They are phytoplankton typically found in freshwater and marine systems, living in both the water column and sediment. Microalgae, capable of performing photosynthesis, are important for life on earth; they produce approximately half of the atmospheric oxygen and use simultaneously the greenhouse gas carbon dioxide to grow photoautotrophically.

Our strategic collaboration with Next Meats Co., Ltd. should enable us to significantly decrease the time needed for product development, while also providing us a partner who can utilize an existing distribution channel to rapidly bring our future products to market. As part of this collaboration agreement, we intend to utilize the factory at Next Meats, which includes an existing production system already in place, to greatly improve the efficiency of our scientific endeavors.

- 4 -

Table of Contents

On January 12, 2022, Dr. Foods, Inc., a Nevada Company, Mama Foods Co., Ltd., a Japan Company, and White Knight Co., Ltd., a Japan Company entered into a non-definitive agreement, a “Letter of Intent”, whereas it iswas proposed that Dr. Foods, Inc., will acquire 100% of the controlling interest of Mama Foods Co., Ltd. from White Knight Co., Ltd. in exchange for $500,000 coupled with the issuance of 19,500,000 shares of restricted Preferred Stock to White Knight Co., Ltd. The issuance of shares shall be subject to the rules and limitations set ~~forth~~ forth by the Securities Act Rule 144. The terms of this non-definitive agreement may be subject to change.

~~Mama~~On ~~Foods~~March 31, ~~Co.~~2022, ~~Ltd~~ Dr. ~~(“Mama~~ Foods~~”) is a food company founded in Japan in 1958~~, ~~currently offering customers in Japan wholesale and retail~~Inc. ~~products centering on Japanese side dishes, from chilled foods to packed~~ and ~~sterilized food.~~ Mama Foods ~~uses~~mutually ~~ingredients~~agreed ~~carefully~~to ~~taken from~~extend ~~natural~~the ~~kelp~~terms ~~and~~of ~~bonito~~the ~~without~~non-definitive ~~adding~~agreement ~~any~~30 ~~chemical~~more ~~seasonings,~~days ~~preservatives,~~in ~~coloring~~order ~~agents,~~to ~~etc.~~provide ~~Mama~~more ~~Foods~~time ~~has~~to ~~two existing~~prepare ~~“in~~the ~~house”~~books ~~production facilities~~ and ~~produces~~records ~~100%~~ of ~~its~~Mama ~~current~~Foods ~~product offerings~~Co. ~~From time to time~~, itLtd. ~~also~~This ~~produces products~~extension ofperiod ~~other~~had ~~third~~expired ~~parties,~~without ~~including~~the ~~certain~~books ~~products~~and ~~offered~~records ~~for~~of ~~sale~~Mama byFoods ~~Next Meats~~ Co., Ltd., ~~such~~having asbeen ~~“Next~~prepared ~~Kalbi~~or ~~2.0”, a~~progressed ~~boneless~~in ~~short~~any ~~rib~~meaningful ~~made~~capacity. ~~from~~On ~~meat~~May ~~substitutes. Currently~~6, ~~Mama~~2022 ~~Foods~~the ~~employs~~parties ~~approximately~~again 43agreed ~~individuals.~~to Inextend ~~2021,~~the ~~White~~terms ~~Knight~~of ~~Co.,~~the ~~Ltd.~~non-definitive ~~acquired 100% of Mama Foods from its prior controller~~agreement, inhowever ~~exchange~~this ~~for~~time ~~approximately~~with 1an ~~million~~expiration ~~USD.~~date ~~The~~of ~~current~~June ~~website~~30, ~~for Mama Foods~~2022, ~~which~~or ~~includes~~until, ~~additional~~if ~~information,~~agreed ~~can~~upon beby ~~found~~all ~~here:~~parties, ~~mama-foods~~further notice.~~com/en/~~

On ~~March~~June 3130, 2022, Dr ~~Foods, Inc. and Mama Foods mutually agreed to extend~~ the ~~terms of the~~ non-definitive agreement 30terminated ~~more~~without ~~days in order to provide more time to prepare~~ the books and records of Mama Foods Co., Ltd. ~~There~~having isbeen noprepared ~~guarantee~~or ~~that~~progressed ~~this~~to ~~will~~the besatisfaction ~~sufficient~~of ~~time~~the toIssuer. ~~complete~~Upon ~~the~~termination, common management ~~transaction(s)~~of ~~contemplated~~both inMama ~~the~~Foods ~~non-definitive~~Co., ~~agreement~~Ltd. Ifand ~~agreed~~Dr. ~~upon~~Foods, ~~all~~Inc. ~~parties~~verbally ~~may~~agreed ~~elect~~ to ~~further~~ extend the ~~terms~~letter of ~~the Letter~~intent ofindefinitely ~~Intent.~~until further notice.

~~Product~~Mama Foods, Co., Ltd. (s“Mama Foods”) is a food company founded in ~~Active~~Japan ~~Development~~in 1958, currently offering customers in Japan wholesale and retail products centering on Japanese side dishes, from chilled foods to packed and sterilized food. Mama Foods uses ingredients carefully taken from natural kelp and bonito without adding any chemical seasonings, preservatives, coloring agents, etc. Mama Foods has two existing “in house” production facilities and produces 100% of its current product offerings. From time to time, it also produces products of other third parties, including certain products offered for sale by Next Meats Co., Ltd., such as “Next Kalbi 2.0”, a boneless short rib made from meat substitutes. Currently, Mama Foods employs approximately 44 individuals. In 2021, White Knight Co., Ltd. acquired 100% of Mama Foods from its prior controller, in exchange for approximately 1 million USD. The current website for Mama Foods, which includes additional information, can be found here: mama-foods.com/en/

The sole shareholder of Mama Foods is WKC which is owned and controlled by Koichi Ishizuka. Koichi Ishizuka is Chief Executive Officer, Chief Financial Officer, and Director of Dr. Foods, Inc., Mama Foods Co., Ltd. and White Knight Co., Ltd.

Currently, the Company is pending moving forward with the acquisition of Mama Foods Co., Ltd. due to the fact that Mama Foods Co., Ltd. requires, and has yet to complete, a PCAOB audit of its financial statements for the last two fiscal years. At this time, the audit is actively taking place by M&K CPAS, PLLC (“M&K”). However, we understand that progress has been minimal. The exchange of information between Mama Foods Co., Ltd. and M&K has been spearheaded by Koichi Ishizuka, who has minimal time, resources, and expertise to expedite such a process. Koichi Ishizuka has also engaged the services of an accounting professional to better facilitate the exchange of information and communication, however, as mentioned, such efforts have been slow going and progress has been minimal as it relates to the completion of an audit. The Company cannot estimate with any level of certainty how long the aforementioned audit of Mama Foods Co., Ltd. may take to complete. The Company does not intend to acquire Mama Foods Co., Ltd., under any terms, prior to the completion of its PCAOB audit.

The Company does not intend to acquire Mama Foods Co., Ltd., under any terms, prior to the completion of its PCAOB audit for its past two fiscal years. We require that Mama Foods Co., Ltd.’s last two fiscal year ends, at minimum, be audited by a PCAOB.

There is a risk that the audit of Mama Foods Co., Ltd. is not completed at all, and/or that we never acquire Mama Foods Co., Ltd. Even if the acquisition of Mama Foods Co., Ltd. is completed, there is the possibility that the terms of this acquisition, which is non-definitive at this time, may not be considered favorable for the company and/or its shareholders. There are also risks we may not realize further revenues, that we do not grow our business at the rate we expect, that we are unable to fulfill our business agenda, that we are unable to add products to our current lineup, and numerous other risks associated with any start up stage company that one should consider before investing in our common stock. Any investment in our common stock is extremely high risk and should only be made by those who can afford the entire loss of their investment.

Currently Available Products

1. Dr. Foie Gras

Foie gras is a specialty food product made of the liver of a duck or goose. According to French law, foie gras is defined as the liver of a duck or goose fattened by gavage (force feeding). It is a popular and well-known delicacy in French cuisine. Its flavor is described as rich, buttery, and delicate, unlike that of an ordinary duck or goose liver. Foie gras is sold whole or is prepared into mousse, parfait, or pâté, and may also be served as an accompaniment to another food item, such as steak. French law states that "Foie gras belongs to the protected cultural and gastronomical heritage of France."

Gavage-based foie gras production is controversial, due mainly to the animal welfare concerns about force-feeding, intensive housing and husbandry, and enlarging the liver to 10 times its usual volume. A number of countries and jurisdictions have laws against force-feeding, and the production, import or sale of foie gras; even where it is legal, a number of retailers decline to stock it.

Dr. Foie Gras, ~~with development spearheaded by Alexis Guionet, a Chief Executive of Dr. Foods Co., Ltd.,~~ is made from a mix of plant products and certain spices and alcohol seasoning. Currently, the creation of Dr. Foie Gras has been completed to our satisfaction, and we are in the midst of acquiring a patent. Specifically, this patent relates to a process of fermenting nuts or beans (or a mixture of nuts and beans) with fungus. ~~This~~The ~~product~~application number is ~~not a meat substitute, as it utilizes the technology of molecular binding from vegetable proteins~~2022-61974. AsIt ~~such,~~was ~~the~~filed ~~animal~~on ~~welfare~~April ~~concerns associated with traditional foie gras are circumvented in their entirety~~1, ~~while~~2022 ~~the taste~~ and ~~texture~~is ~~of this french delicacy are retained. We believe~~still ~~that~~pending ~~this will open up sales and distribution channels that have been closed to traditional foie gras~~review. ~~We believe that the demand for an alternative to traditional foie gras, due to increased regulations, and an ethical focus on animal welfare, has never been higher.~~

2This product is not a meat substitute, as it utilizes the technology of molecular binding from vegetable proteins. ~~Microalgae~~As ~~foods~~such, the animal welfare concerns associated with traditional foie gras are circumvented in their entirety, while the taste and texture of this french delicacy are retained. We believe that this will open up sales and distribution channels that have been closed to traditional foie gras. We believe that the demand for an alternative to traditional foie gras, due to increased regulations, and an ethical focus on animal welfare, has never been higher.

~~Microalgae~~At isthe anpresent ~~ingredient full of potential~~time, ~~being~~ ~~rich in numerous health-beneficial compounds such as omega-3 long-chain polyunsaturated fatty acids~~Dr. InFoie aGras ~~search~~is manufactured ~~for~~by ~~more~~Mama ~~sustainable food~~Foods ~~systems~~Co., ~~microalgae~~Ltd. ~~are~~The ~~considered~~company ~~one~~sells of the ~~most~~products ~~auspicious sustainable sources~~ of ~~food~~Mama ~~ingredients.~~Foods ~~Photoautotrophic microalgae have a higher growth efficiency compared~~ to ~~conventional~~its ~~crops,~~own ~~do not need arable land~~customers, and ~~substantially~~Mama ~~contribute~~Foods tofulfills ~~capturing~~the ~~atmospheric CO2~~orders. ~~While heterotrophic microalgae use other carbon sources and do not therefore contribute to CO2 capture, they are often characterised by an even higher biomass productivity.~~

~~When the annual production of 1 ha of soybean is converted into protein, it is 0.6 tons per year, but algae~~ Product(~~spirulina~~s) can be produced at 9 tons per year which is 15 times more. In addition, it can be cultivated wherever there is water and light, and it is possible to utilize land that cannot be used for agricultural, such as deserts and wastelands. It is thought to be the first step in ~~solving the problem of the shortage of agricultural land.~~Active Development

WeAll ~~are~~of inthe ~~active~~below products have development ofcosts ~~new~~which ~~products that~~are ~~use~~paid ~~microalgae~~for asjointly aby ~~base~~Mama inFoods ~~order~~Co., toLtd. ~~support~~ and ~~improve~~Dr. ~~the~~Foods. ~~overall~~Specifically, ~~health~~at ofthis ~~the~~time, ~~consumer.~~Mama ~~Presently~~Foods Co., weLtd. is ~~are~~paying ~~researching~~for amachinery ~~micoralgae hamburger,~~costs asand ~~well~~for asthe ~~genetically~~cost ~~modified~~of ~~soybeans.~~one Insupport ~~the~~staff ~~future~~member, ~~potentially~~whereas byDr. Foods is paying for the ~~end~~salaries of ~~2022~~Mr. Ido and Dr. Patuk, wewho ~~anticipate~~are ~~that~~the ~~research~~individuals ~~and~~primarily responsible for development of athe ~~host~~below products. The allocation of ~~different~~product development ~~microalgae~~costs ~~products~~have ~~will~~not ~~begin~~been formally decided, and may be altered at any time.

1. Vegan Caviar- Development of vegan caviar has completed, and we are in the midst of developing a machine for mass production.

2. Cultured Caviar- We obtain cultured fish fat from a Singapore company and we use this cultured fish fat to make cultured caviar. Development remains ongoing.

3. Vegan Truffle Butter- This product is created through a mixture of vegan butter and truffles. Development remains ongoing.

Pending Collaborative Development

1. Next Kalbi Chips- We have entered into a collaborative effort wherein we dedicate our staff, along with the staff of Mama Foods Co., Ltd., to develop and produce Next Kalbi Chips (this is a short-rib style alternative meat product) for Next Meats Co., Ltd. When this product is finalized, Mama Foods Co., Ltd. plans to sell the Next Kalbi Chips to Next Meats Co., Ltd., who plan to then sell the Next Kalbi Chips to their clients.

Although our staff is collaborating with the development of the Next Kalbi Chips, at this point in time Dr. Foods, Inc., and its subsidiaries, will not generate any revenue, and do not benefit in any material way, from this collaborative effort. We believe that the only circumstance in which we would benefit from this arrangement would be if we were to acquire Mama Foods Co., Ltd. There is a risk that the audit of Mama Foods Co., Ltd. is not completed at all, and/or that we never acquire Mama Foods Co., Ltd. Even if the acquisition of Mama Foods Co., Ltd. is completed, there is the possibility that the terms of this acquisition, which is non-definitive at this time, may not be considered favorable for the company and/or its shareholders.

Other Collaborations

Suspended Product Development

As of March 2023, we have suspended development of microalgae foods. At this point in time, there are no plans to resume development of microalgae foods.

Marketing Strategy

Our marketing ~~initiatives~~efforts ~~will be conducted, at present, by Next Meats Co., Ltd., with whom we~~ have ~~entered into a Collaboration Agreement. Our company motto~~, ~~which~~thus ~~is comparable~~far, tobeen ~~that~~constrained ~~of Next Meats, is~~ to ~~“Save~~hosting ~~the~~two ~~Earth~~press ~~with~~conferences ~~the Power of Science”,~~ and ~~it is this philosophy upon which~~ we intend ~~for all of our marketing~~ to bepublish ~~based.~~press ~~Although~~releases wewith ~~will~~any ~~initially~~notable ~~rely~~updates ~~entirely~~to ~~upon~~our ~~Next Meats Co~~business activities., ~~Ltd.,~~Any ~~specifically~~further ~~upon its existing~~ marketing ~~department~~efforts ~~and staff~~remain, inat ~~order~~this ~~to conduct all marketing activities~~time, ~~there~~under isconsideration ~~the~~and ~~possibility~~we ~~that~~cannot asstate ~~our~~with ~~operations~~any ~~progress~~level of ~~that~~specificity when we ~~may~~will ~~independently~~conduct ~~begin~~additional marketing activities ~~on our own behalf. In such an event~~, ~~our~~or ~~future~~what those marketing activities may be ~~altered significantly, although we cannot predict to what extent at the current time~~.

- 5 -

Table of Contents

~~Expansion~~Future Plans

Given the nature of our business is highly dependent upon the progress of our research and development of plant-based foods, it is possible that any and all plans may be either sped up, or experience a delay, depending on the progress of our research efforts. Further, when our products begin distribution, we may find that our plans may be materially altered, expanded, or curtailed as dictated by market forces at the time. As such, our ~~expansion~~future plans should be read as a framework ~~for our future goals~~, but not a guarantee that we will carry out any or all such operations in the indicated timeline.

At present our ~~expansion~~future plans are as follows:

We ~~anticipate~~intend ~~that~~to byoffer ~~the~~our ~~end~~foie ofgras ~~2022, that~~and ~~Dr.~~caviar ~~Foie Gras will be patented and we will begin the process of bringing Dr. Foie Gras~~ to ~~market.~~various ~~The~~restaurants, ~~patent application has been submitted to the Japanese patent office~~hotels, and weother ~~may~~venues ~~currently~~over ~~continue to modify~~ the ~~content~~remainder of the ~~patent,~~2023 iffiscal ~~necessary, prior to rendering payment, at which point our patent will be examined and reviewed~~year. ~~After~~We ~~we obtain the patent, we~~ intend to ~~utilize~~begin ~~the~~sales ~~factory and production line~~ of our caviar ~~strategic~~and ~~partner,~~vegan ~~Next~~truffle ~~Meats Co.~~butter, ~~Ltd.,~~but ~~with whom~~ we ~~have~~cannot ~~entered~~determine ~~into~~specifically awhen ~~Collaboration~~such ~~Agreement,~~sales toefforts ~~begin~~will ~~large scale production and distribution efforts~~commence. ~~At present~~Further, we ~~have~~will ~~completed~~also continue active development of ~~two~~additional ~~types of Foie Gras~~products, ~~which~~although we ~~intend~~cannot tostate ~~announce officially within the coming months. Further, it is our intention to oversee the formation of contracts and agreements~~ with ~~restaurants/specialty trading~~any ~~companies~~certainty ~~that~~when ~~have~~such adevelopment demand for our product(s). This may include, but not strictly be limited to, grilled meat chains or burger chains (Wayback Burgers as an example). We also intend, by the third quarter of 2022, we will begin efforts ~~to develop overseas agreements,~~will ~~with~~be ~~a particular focus on China, India, and Singapore at present~~concluded.

~~Over~~Our ~~the~~CEO, ~~course~~Koichi ~~of 2022~~Ishizuka, ~~we intend to continue~~has ~~research~~been ~~on microalgae, specifically how it may be used~~ in ~~food~~verbal ~~products,~~discussions ~~and~~with ~~develop~~principals ~~products~~of ~~for~~various ~~both~~wedding ~~domestic~~ and ~~overseas~~hotel ~~markets. We cannot~~venues, ateach ~~this point in time, speak with any level~~ of ~~specificity~~which asindicated tothat ~~the~~they ~~nature~~may ofbe ~~the~~interested in ~~products~~offering weour ~~may~~vegan ~~develop~~foie ~~from~~gras ~~microalgae,~~ as ~~research~~a ~~efforts~~menu ~~are ongoing~~option. ~~During~~It ~~this~~is ~~time~~important weto ~~also~~note ~~have~~that ~~plans,~~no ~~which~~revenue ~~cannot~~has bebeen ~~defined~~realized ~~with any specificity at present,~~ to ~~seek out~~date ~~potential~~from ~~partnerships~~these discussions, ~~potentially acquisitions,~~ and tono ~~expand~~written ~~upon~~or ~~our~~verbal ~~distribution~~agreements ~~network~~have ~~while~~materialized ~~taking~~as ~~steps towards~~ a ~~speculative NASDAQ~~result ~~listing~~of inthese ~~2023~~discussions. However, ~~Such~~as mentioned, athere ~~listing~~is ~~would~~no ~~only~~guarantee ~~occur~~that ifthey wewill ~~were~~do toso ~~meet~~in the ~~requirements of NASDAQ at that point in time, which remains highly uncertain~~future.

We hope that by the conclusion of this fiscal year that we will have completed the acquisition of Mama Foods Co., Ltd., however, as previously stated, we cannot predict with any level of certainty when the PCAOB audit of Mama Foods Co., Ltd. will conclude, and therefore we cannot predict when we may be able to complete this acquisition. Prior to any acquisition of Mama Foods Co., Ltd., we require that Mama Foods Co., Ltd.’s last two fiscal year ends, at minimum, be audited by a PCAOB. There is a risk that the audit of Mama Foods Co., Ltd. is not completed at all, and/or that we never acquire Mama Foods Co., Ltd. Even if the acquisition of Mama Foods Co., Ltd. is completed, there is the possibility that the terms of this acquisition, which is non-definitive at this time, may not be considered favorable for the company and/or its shareholders.

Additionally, we are exploring the possibility of moving from the OTC Pink Tier onto the OTCQB. Such efforts are, at this stage, exploratory, and we cannot state with certainty when, or if, they will be concluded.

Government Regulations

The below does not extensively detail every law and regulation to which the Company may be subject to, but rather provides an overview of the kind of food safety standards to which our product(s) will be held.

The main law that governs food quality and integrity in Japan is the Food Sanitation Act ("FSA") and the law that comprehensively governs food labelling regulation is the Food Labelling Act.

The FSA regulates food quality and integrity by:

- Establishing standards and specifications for food, additives, apparatus, and food containers and packaging;

- Providing for inspection to see whether the established standards are met;

- Providing for hygiene management in the manufacture and sale of food; and

- Requiring food businesses to be licensed.

Under the FSA, additives and foods containing additives must not be sold, or be produced, imported, processed, used, stored, or displayed for marketing purposes unless the Minister of Health, Labour and Welfare ("MHLW") has declared them as having no risk to human health after seeking the views of the Pharmaceutical Affairs and Food Sanitation Council ("PAFSC"). In addition, it is not permissible to add any processing aids, vitamins, minerals, novel foods or nutritive substances to food unless they have been expressly declared by the MHLW as having no risk to human health.

The MHLW may establish specifications for methods of producing, processing, using, cooking, or preserving food or additives to be served to the public for marketing purposes ("Specifications"), or may establish standards for food ingredients or additives to be served to the public for marketing purposes ("Standards") pursuant to the FSA. Accordingly, where substances are allowed to be added to food, they may only be used within the limits expressly set by the Specifications and Standards.

Employees

Currently, we, “Dr. Foods, Inc.”, have only one employee, our sole officer and Director Koichi Ishizuka, who is not compensated at present for his services. ~~Our~~However, ~~wholly~~pursuant ~~subsidiary,~~to ~~Dr.~~an ~~Foods~~arrangement with Next Meats Co., Ltd., ~~has~~a ~~four~~Japan ~~officers~~Corporation, ~~Koichi~~Next ~~Ishizuka~~Meats Co., ~~Chief~~Ltd. ~~Executive~~provides ~~Officer,~~temporary ~~and~~employees (staff) ~~three~~to ~~Executive Officers,~~our ~~Dr.~~Company ~~Alexis~~as ~~Guionet,~~needed ~~Dr.~~to Yufurther ~~Lu,~~our ~~and~~business Dragenda. ~~Laroslav~~Regarding ~~Patuk.~~this ~~The~~arrangement, ~~biographical~~we ~~information~~are ~~for~~billed ~~Mr.~~by ~~Koichi~~Next ~~Ishizuka~~Meats isCo. ~~detailed~~Ltd. ~~herein~~ on ~~page~~a case 10by ~~and~~case basis depending on the ~~biographical~~amount ~~information~~of ~~for~~staff ~~Dr.~~and ~~Alexis~~hours ~~Guionet,~~allocated ~~Dr.~~by Yueach ~~Lu,~~staff ~~and~~member ~~Dr.~~to ~~Laroslav~~our ~~Patuk~~business isendeavors, ~~directly~~primarily ~~below:~~consisting of research and development.

Our wholly subsidiary, Dr. ~~Alexis~~Foods ~~Guionet~~Co., ~~(Doctor~~Ltd. has three officers, Koichi Ishizuka, Chief Executive Officer, and two Executive Officers, Iaroslav Patuk and Hideo Fujioka. Currently, and as of ~~Biology)~~April 2023, there is one Officer and Director of DRFS Singapore, which is Mr. Koichi Ishizuka. Any and all previous officers and directors of DRFS Singapore are no longer with DRFS Singapore.

Alexis Guionet, age 35, graduated from Burgundy University, France, in 2008 with a License in “Science, Technology, Health: option Biology”. He earned his first Master’s Degree in “Health Biology; option Plant Biology” from Burgundy Univeristy in 2009 and his second Master’s Degree in “Nanotechnology and Nanobioscience” in 2010. In 2014 he earned his PhD in in Biophysics at the Institute of Pharmacology and Structural Biology – CNRS / Toulouse III University, France.

From 2010 to 2014, Dr. Guionet was a researcher at Veolia Environment Research and Innovation, in the department “Health and Environment” Maisons Laffite, France, where he worked on the development of a prototype for bacteria destruction by electric fields. From 2015 to 2018, Dr. Guionet was employed as a postdoctoral researcher at the Institute of Pulsed Power Science at Kumamoto University in Japan, where he researched Hydrocarbons extraction from micro-algae by electric field, arc discharge and shock wave, calcium uptake by HeLa cells submitted to electric field and shock waves for essential oil extraction from plants and yeast inactivation. From 2018 to 2020, Dr. Guionet was employed as a postdoctoral researcher at the National Institute of Material Science in Tsukuba, Japan, where he researched electrochemistry of biofilms, the study of pathogens and anaerobic bacteria, using potentisostat and nanoSIMS. From 2020 to present, Dr. Guionet has been employed as a postdoctoral researched at the Faculty of Science and Engineering at Iwate University in Japan, where he researches pulse power applied on agriculture, spore control by dielectric barrier discharge, and fungal fructification by pulsed electric field. In addition, Dr. Guionet has contributed to numerous publications in peer review over the course of his career.

Dr. Yu Lu (Doctor of Life Sciences)

Yu Lu, age 35, graduated from Beijing University of Agriculture, in Beijing, China, in 2008 with a Bachelors Degree in Biotechnology. In 2017, Dr. Lu earned his Master’s Degree and Ph.D in Life Science from Hokkaido University in Sapporo, Japan. From April 2012 to March 2017, he was a Graduate Researcher, at Hokkaido University, where he researched the functional analysis of ABI1 mediated plant C/N balance regulation in Arabidopsis and functional characterization of conventional C/N regulators, ATL31 and 14-3-3 in tomatoes. Also during this time, and at Hokkaido University, he was a Teaching Assistant for the Practice of Cell Structure and Function and the Practice of Biological Science Research.

From September of 2017 to November of 2017, Dr. Lu was a Guest Postdoctoral Fellow at the Max Planck Institute of Molecular Plant Physiology, where he researched Primary metabolites profiling with SnRK1 double knockdown mutant under different C/N condition in Arabidopsis. From April 2017 to March 2018, Dr. Lu was a Postdoctoral Fellow at Hokkaido University where he researched the functional analysis of SnRK1 pathway involved in plant C/N balance regulation. From April 2018 to March 2019, Dr. Yu was a Postdoctoral Researcher at the University of Tsukaba, where he researched a Cross-ministerial Strategic Innovation Promotion Program (SIP) project. From November 2018 to November of 2020, Dr. Lu was a Postdoctoral Researched at the University of Tsukuba.

Dr. Laroslav Patuk (Doctor of Science and Engineering)

Laroslav Patuk, age 27, graduated from the Institute of Mechanization of Agriculture, Primorskaya State Academy of Agriculture, in 2015, where he earned his Bachelors in Agricultural Engineering. In 2017, Dr. Patuk graduated from the Erasmus plus exchange program, Institute of Mechanical Engineering, Faculty of Production Engineering, Warsaw University of Life Sciences. Also in 2017, Dr. Patuk graduated from the Faculty of Mechanization of Agriculture, Stavropol State Agrarian University, where he earned his Master’s Degree in Agricultural Engineering. In 2020, Dr. Patuk earned his Ph.D in Agriculture from the Graduate School of Science and Technology, Niigata University, Japan.

In November of 2016, Dr. Patuk was a Researcher at the Institute of Mechanical Engineering at Warsaw University of Life Sciences. In April of 2019, Dr. Patuk served as a Teaching Assistant at the Laboratory for Bioproduction and Machinery, Faculty of Agriculture, at Niigata University. From October of 2020 to Present, Dr. Payuk has been employed as a Postdoctoral Researcher at the Laboratory for Bioproduction and Machinery, Faculty of Agriculture, Graduate School of Science and Technology, at Niigata University.

Competition

The plant-based food industry is highly competitive, with a major market share held by prominent companies, such as Impossible Foods, an American food technology company that manufactures and develops plant-based artificial meats and dairy products with its headquarters in Redwood City, California. Their corporate value is estimated at $10 billion and the number of stores that stock their products has gone from 150 to 20,000 over the course of one year (as of May 4, 2021). We have direct competition in regards to our future microalgae product offerings as well, specifically Sophie’s BioNutrients, a Singapore Biofood technology company, has created milk derived from microalgae, and New Wave Foods has created shrimp products from microalgae, and hopes to product new lobster, scallops and crab products from microalgae in the future.

Despite ~~these~~this, and other, competitors, we we believe that we have competitive strengths which poise Dr. Foods, Inc. to become a prominent market participant in the plant based food industry going forward. Our wholly owned subsidiary Dr. Foods Co., Ltd., through which we operate at this time, is staffed with researchers with high technical capabilities from all over the world, and know-how to molecularly bind and form plant proteins from powder. ~~We have the capability to enter into mass production by utilizing the existing production line of Next Meats Co.~~Additionally, ~~Ltd., as a result of the collaboration agreement~~ we ~~have entered into with Next Meats Co., Ltd. Further, we~~ believe that ~~the business experience, and existing business relationships, established by~~ our executive officer, will allow us to enter into the market expeditiously and may lead to future collaborate business arrangements that are highly beneficial to the company and its shareholders. Additionally, our goal to “save the next generation of ‘food’ through science and technology” is one that we believe resonates with an increasingly wellness conscious population that seeks to decrease many of the environmental issues facing the world today caused by, in what we believe is a considerable part, the existing meat market, .

Item 1A. Risk Factors.

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

WeAt this time, we neither rent nor own any properties. We utilize the office space and equipment of Next Meats Co., Ltd., a Japanese Company, as well as office space of our management, at no cost. Management estimates such amounts to be immaterial.

Item 3. Legal Proceedings.

From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition or results of operations. We may become involved in material legal proceedings in the future.

Item 4. Mine Safety Disclosures.

Not applicable.

- 6 -

Table of Contents

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is currently quoted on the OTC Pink Tier under the symbol “DRFS” There is currently a limited trading market in the Company’s shares of common stock.

Over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

Quarter Ended	High Bid	Low Bid
June 30, 2021 1	$09.~~0244~~02	$01.~~0097~~94
September 30, 2021	$014.~~071~~20	$02.~~0135~~70
December 31, 2021	$09.~~0456~~12	$01.~~009~~80
March 31, 2022	$03.~~0197~~94	$0.~~0027~~54
June 30, 2022	$0.94	$0.42
September 30, 2022	$3.78	$0.30
December 31, 2022	$0.959	$0.272
March 31, 2023	$0.45	$0.11

¹We were a party to a corporate reorganization, legally effective April 28, 2021. Information regarding this reorganization is detailed herein on page 4. Prior to this reorganization, we have no information to report pursuant to the above table. The quarter ending June 30, 2021 only includes data stemming back to April 28, 2021.

Holders

As of ~~the~~August ~~date~~16, ~~of this report~~2023, the Company ~~has~~ 2has 13,~~622~~708,~~968,890~~699 shares of common stock issued and outstanding and 10,000 shares of Series Z preferred stock issued and outstanding, ~~which~~ which number of issued and outstanding shares of common stock and preferred stock have been used throughout this report.

As of ~~the~~August ~~date~~16, ~~of this report~~2023, we have approximately ~~176~~177 shareholders of record of our common stock. This is inclusive of Cede and Co., which is deemed to be one shareholder of record. For further clarification, Cede & Co. is currently defined by the “NASDAQ”, as “a Nominee name for The Depository Trust Company, a large clearing house that holds shares in its name for banks, brokers and institutions in order to expedite the sale and transfer of stock.”

Dividends and Share Repurchases

We have not paid any dividends to our ~~shareholder~~shareholders. There are no restrictions which would limit our ability to pay dividends on common equity or that are likely to do so in the future.

Issuer Purchases of Equity Securities

None.

Equity Compensation Plan Information

Not applicable.

Recent Sales of Unregistered Securities; Uses of Proceeds from Registered Securities

On or about May 31, 2022, we sold ~~307~~1,~~692~~538,~~308~~ 462 shares of restricted Common Stock to SJ Capital Co., Ltd., a Japanese Company, atfor proceeds totaling approximately $769,231. aThe price paid per share of restricted Common Stock was approximately $0.~~0025 USD~~ 50 per share. We believe SJ Capital Co., Ltd. may be deemed to be a related party as they hold over 10% of the shares of our class of Common Stock.

The proceeds from this sale are to be used by the Company for working capital.

~~The~~On ~~aforementioned~~or ~~sale~~about ofJune ~~shares~~26, ~~was~~2023, ~~conducted~~the ~~pursuant~~company toconsummated ~~Regulation~~an Sagreement offor the ~~Securities~~sale ~~Act~~ of ~~1933~~593,811 asshares ~~amended~~of ~~("Regulation~~restricted ~~S").~~Common ~~The sale~~Stock ofto ~~shares~~Ultimate ~~was~~One LLC, ~~made~~a ~~only~~Japanese toCompany, ~~non-U.S.~~at ~~persons/entities~~a ~~(as~~price ~~defined~~of ~~under~~$0.315 ~~Rule~~per ~~902~~share ~~section (k)(2)(i)~~ of ~~Regulation~~Common ~~S),~~Stock. ~~pursuant~~The ~~to offshore~~transaction ~~transactions~~was completed, and norecorded ~~directed~~by ~~selling~~the ~~efforts~~Company’s transfer ~~were~~agent, ~~made~~on inJune ~~the~~30, ~~United~~2023. ~~States~~The bytotal ~~the~~subscription ~~issuer,~~amount apaid ~~distributor,~~by ~~any~~Ultimate ofOne ~~their~~LLC ~~respective affiliates,~~was orapproximately ~~any~~$187,050. ~~person~~Ultimate ~~acting~~One onLLC is ~~behalf~~not ofa ~~any~~related ofparty to the ~~foregoing~~Company.

~~Following~~The ~~the~~proceeds ~~sale~~from ofthis ~~restricted~~sale ~~common~~are ~~shares~~ to SJbe ~~Capital~~used ~~Co.,~~by ~~Ltd., we now have 2,622,968,890 shares of Common Stock issued and outstanding as of~~ the ~~date~~Company offor ~~this~~working ~~report~~capital.

The aforementioned sales of shares were conducted pursuant to Regulation S of the Securities Act of 1933, as amended ("Regulation S"). The sales of shares were made only to non-U.S. persons/entities (as defined under Rule 902 section (k)(2)(i) of Regulation S), pursuant to offshore transactions, and no directed selling efforts were made in the United States by the issuer, a distributor, any of their respective affiliates, or any person acting on behalf of any of the foregoing.

- 7 -

Table of Contents

Item 6. Selected Financial Data.

Not applicable because the Company is a smaller reporting company.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.”

These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Liquidity and Capital Resources

As of March 31, ~~2022 and 2021~~2023, we had cash and cash equivalents in the amount of $1,365, compared to $0 as of March 31, 2022. Currently, our cash balance is not sufficient to fund our operations and our revenues ~~cannot~~are not sufficient to cover our ~~cost~~costs and expenses for any substantive period of time. We have been utilizing, and may utilize, funds from ~~OFF~~Koichi ~~Line~~Ishizuka, Coour CEO. However, ~~Ltd.~~there is no formal agreement, ~~owned~~arrangement ~~and~~or ~~managed~~legal byobligation to ~~Koichi~~advance ~~Ishizuka,~~or ~~our~~loan ~~CEO.~~funds to the company between Dr. Foods, Inc., and Koichi Ishizuka,. ~~however,~~We ~~have~~may noalso ~~formal commitment,~~seek ~~arrangement~~to orsell ~~legal~~shares ~~obligation~~of toour ~~advance~~common orstock in ~~loan~~order ~~funds~~ to ~~the~~fund ~~company~~our business activities. In order to implement our plan of operations for the next twelve-month period, we require further funding. Being a start-up stage company, we have very limited operating history. After a twelve-month period we may need additional financing but currently do not have any arrangements for such financing.

If we need additional cash and cannot raise it, we will either have to suspend operations until we do raise the cash we need, or cease operations entirely.

Revenues

For the ~~years~~year ended March 31, ~~2022 and 2021~~2023, we generated norevenue in the amount of $1,038. This revenue was generated as a result of commencing efforts to sell products, in this instance vegan foie gras, to customers. We are considered to be a reseller, as the products we offer are currently manufactured by Mama Foods Co., Ltd. (“Mama Foods”).

The sole shareholder of Mama Foods is White Knight Co., Ltd., a Japan entity, which is owned and controlled by Koichi Ishizuka. Koichi Ishizuka is Chief Executive Officer, Chief Financial Officer, and Director of Dr. Foods, Inc., Mama Foods Co., Ltd. and White Knight Co., Ltd.

For the year ended March 31, 2022, we generated no revenue, and we had not yet sold any products.

Net Loss

We recorded a net loss of $1321,~~047,108~~820 and $51,~~760~~047,108 for the years ended March 31, ~~2022~~2023 and ~~2021~~2022, respectively. The variance in net loss is attributed to a decrease in general and administrative expenses during the March 31, 2023 fiscal year.

Cash ~~flow~~flows

For the years ended March 31, ~~2022~~2023 and ~~2021~~2022, cash used in operating activities was $43(293,~~858~~628) and $2(48,~~010~~858) respectively. ~~Negative~~For ~~cash~~both ~~flow~~periods, ~~resulted~~it ~~due~~is to the Company’s ~~fact~~belief that wethe ~~incurred~~negative ~~expense~~cash ~~costs~~flow ~~and~~was weprimarily ~~have~~attributable ~~not begun~~ to ~~generate~~our ~~any~~incurred ~~revenue~~net loss.

For the years ended March 31, ~~2022~~2023 and ~~2021~~2022, cash provided by investing activities was $(527,675) and $0, respectively. The variance between periods is primarily attributable to a related party loan in the amount of $(710,700).

~~Working~~Total ~~capital~~Liabilities

As of March 31, ~~2022~~ 2023 and ~~2021~~2022, we had atotal ~~working~~liabilities ~~deficit~~in the amount of $40,122 and $7,000, ~~and~~respectively. ~~working~~As ~~deficit~~of March 31, 2023, this was primarily attributable to accounts payable - related party, whereas as of $3March 31,~~750~~ 2022, ~~respectively~~which was primarily attributable to accrued expenses.

Additional Paid-In Capital

The Company’s sole officer and Director, Koichi Ishizuka, paid expenses on behalf of the company and its wholly owned subsidiary totaling $67,574 during the year ended March 31, 2023. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

The Company’s sole officer and Director, Koichi Ishizuka, paid expenses on behalf of the Company and its wholly owned subsidiary totaling $36,758 during the period ended March 31, 2022. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $7,100 during the period ended March 31, 2022. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

Letter of Intent- Non-Definitive Agreement

On January 12, 2022, Dr. Foods, Inc., a Nevada Company, Mama Foods Co., Ltd., a Japan Company, and White Knight Co., Ltd., a Japan Company entered into a non-definitive agreement, a “Letter of Intent”, whereas it was proposed that Dr. Foods, Inc., will acquire 100% of the controlling interest of Mama Foods Co., Ltd. from White Knight Co., Ltd. in exchange for $500,000 coupled with the issuance of 19,500,000 shares of restricted Preferred Stock to White Knight Co., Ltd. The issuance of shares shall be subject to the rules and limitations set forth by the Securities Act Rule 144.

White Knight Co., Ltd. is a Japanese entity owned and controlled by Koichi Ishizuka.

Mama Foods, Co., Ltd. (“Mama Foods”) is a food company founded in Japan in 1958, currently offering customers in Japan wholesale and retail products centering on Japanese side dishes, from chilled foods to packed and sterilized food. Mama Foods uses ingredients carefully taken from natural kelp and bonito without adding any chemical seasonings, preservatives, coloring agents, etc. Mama Foods has two existing “in house” production facilities and produces 100% of its current product offerings. From time to time, it also produces products of other third parties, including certain products offered for sale by Next Meats Co., Ltd., such as “Next Kalbi 2.0”, a boneless short rib made from meat substitutes. Currently, Mama Foods employs approximately 44 individuals. In 2021, White Knight Co., Ltd. acquired 100% of Mama Foods from its prior controller, in exchange for approximately 1 million USD. The current website for Mama Foods, which includes additional information, can be found here: mama-foods.com/en/

On March 31, 2022, Dr. Foods, Inc. and Mama Foods mutually agreed to extend the terms of the non-definitive agreement 30 more days in order to provide more time to prepare the books and records of Mama Foods Co., Ltd. This extension period had expired without the books and records of Mama Foods Co., Ltd. having been prepared or progressed in any meaningful capacity. On May 6, 2022 the parties again agreed to extend the terms of the non-definitive agreement, however this time with an expiration date of June 30, 2022, or until, if agreed upon by all parties, further notice.

On June 30, 2022, the non-definitive agreement terminated without the books and records of Mama Foods Co., Ltd. having been prepared or progressed to the satisfaction of the Issuer. Upon termination, common management of both Mama Foods Co., Ltd. and Dr. Foods, Inc. verbally agreed to extend the letter of intent indefinitely until further notice.

The Company does not intend to acquire Mama Foods Co., Ltd., under any terms, prior to the completion of Mama Foods Co., Ltd.’s PCAOB audit for its past two fiscal years. We require that Mama Foods Co., Ltd.’s last two fiscal year ends, at minimum, be audited by a PCAOB.

The efforts to spearhead preparation of the books and records had been, and continues to be, led by Koichi Ishizuka who has outside business interests and other demands upon his time that limit his availability. It should also be noted that he does not have expertise in accounting matters. As such, the Company has engaged outside accounting expertise to assist in this process. The Company cannot state, with any level of certainty, when, or if, the books and records will be prepared to the satisfaction of the Issuer, and as such, when the books and records of Mama Foods Co., Ltd. will be fully audited by a PCAOB auditor.

Currently, the Company is pending moving forward with the acquisition of Mama Foods Co., Ltd. due to the fact that Mama Foods Co., Ltd. has yet to complete, a PCAOB audit of its financial statements for the last two fiscal years. At this time, the audit is actively taking place by M&K CPAS, PLLC (“M&K”). However, we understand that progress has been minimal.

The Company cannot estimate with any level of certainty how long the aforementioned audit of Mama Foods Co., Ltd. may take to complete. The Company does not intend to acquire Mama Foods Co., Ltd., under any terms, prior to the completion of its PCAOB audit.

Going Concern

The ~~accompanying~~Company’s ~~consolidated~~ financial statements are prepared in onaccordance awith ~~basis~~generally ofaccepted accounting ~~assuming~~principles ~~that~~applicable ~~the~~to ~~Company is~~ a going concern that contemplates the realization of assets and ~~satisfaction~~liquidation of liabilities in the normal course of business. The Company isdemonstrates inadverse ~~the~~conditions ~~early~~that ~~stage of operations and has reoccurring net losses and negative cash flows. These factors~~ raise substantial doubt about the Company’'s ability to continue as a going concern~~. The~~ ~~Company~~for ~~will~~one ~~offer~~year ~~noncash~~following ~~consideration~~the ~~and~~issuance ~~seek equity lines as a means~~ of ~~financing~~these ~~its~~financial ~~operations~~statements. IfThese ~~the~~adverse conditions ~~Company~~are isnegative ~~unable~~financial ~~to obtain~~trends, ~~revenue-~~specifically ~~producing~~operating ~~contracts~~loss, orworking ~~financing~~capital ordeficiency, ifand ~~the~~other ~~revenue~~adverse orkey ~~financing~~financial itratios. The ~~does~~Company ~~obtain~~has isnot ~~insufficient~~established sufficient revenue to cover ~~any~~its operating ~~losses~~ itcosts. ~~may~~Management ~~incur,~~plans itto ~~may~~fund ~~substantially~~operating ~~curtail~~expenses orwith ~~terminate~~related party ~~its~~contributions ~~operations~~to orcapital. ~~seek~~There ~~other~~is ~~business~~no ~~opportunities~~assurance ~~through strategic alliances, acquisitions or other arrangements~~ that ~~may~~management's ~~dilute~~plan ~~the~~will ~~interests~~be ofsuccessful. ~~existing~~The ~~stockholders.~~financial ~~However,~~statements ~~management~~do ~~cannot~~not ~~provide~~include any ~~assurances~~adjustments ~~that~~relating to the ~~Company~~recoverability ~~will~~and beclassification ~~successful~~of inrecorded ~~accomplishing~~assets, ~~any~~or ofthe ~~its~~amounts ~~plans.~~and ~~The~~classification ~~accompanying~~of ~~financial~~liabilities that ~~statements~~might dobe ~~not~~necessary ~~include any~~in ~~adjustments~~the event that ~~might~~the ~~result~~Company ~~from~~cannot ~~the~~continue ~~outcome~~as ofa ~~this~~going ~~uncertainty~~concern.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

As a “smaller reporting company”, we are not required to provide the information required by this Item.

- 8 -

Table of Contents

Item 8. Financial Statements and Supplementary Data.

		Pages
Report of Independent Registered Public Accounting Firm (PCAOB FIRM ID - 5041)		F2
Report of Independent Registered Public Accounting Firm (PCAOB FIRM ID - 2738)		F2
Condensed Consolidated Balance Sheets		F3
Report of Former Independent Registered Public Accounting Firm (PCAOB FIRM ID - 5041)		F3
Condensed Consolidated Statement of Operations		F4
Consolidated Balance Sheets		F4
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit)		F5
Consolidated Statements of Operations		F5
Condensed Consolidated Statement of Cash Flows		F6
Consolidated Statement of Changes in Stockholders’ Equity (Deficit)		F6
Notes to Condensed Consolidated Financial Statements		F7-F8
Consolidated Statements of Cash Flows		F7
Notes to Condensed Consolidated Financial Statements		F8-F9

- F1 -

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Dr. Foods, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Dr. Foods, Inc. (the Company) as of March 31, 2023, and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows for the year ended March 31, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2023, and the results of its operations and its cash flows for the year ended March 31, 2023, in conformity with accounting principles generally accepted in the United States of America. The consolidated financial statement of Dr. Foods, Inc. as of March 31, 2022 were audited by other auditors whose report dated June 13, 2022 expressed an unqualified opinion on those statements.

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the Company had a net loss from continuing operations and a working capital deficiency which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are discussed in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

Going Concern

As discussed in Note 3 to the consolidated financial statements, the Company had a net loss from continuing operations and a working capital deficiency.

Auditing management’s evaluation of a going concern can be a significant judgement given the fact that the Company uses management estimates on future revenues and expenses which are not able to be substantiated.

To evaluate the appropriateness of the going concern, we examined and evaluated the financial information that was the initial cause along with management’s plans to mitigate going concern and management’s disclosure on going concern.

/s/ M&K CPAS, PLLC

M&K CPAS, PLLC

We have served as the Company’s auditor since 2023

Firm ID 2738

Houston, TX

August 16, 2023

- F2 -

Table of Contents

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Dr. Foods, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance ~~sheets~~sheet of Dr. Foods, Inc. as of March 31, 2022 ~~and 2021~~, the related statements of operations, stockholders' equity (deficit), and cash flows for the ~~years~~year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2022 and ~~2021, and~~ the results of its operations and its cash flows for the ~~years~~year then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/S/ BF Borgers CPA PC

BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company's auditor ~~since~~from 2021 to 2022

Lakewood, CO

June 13, 2022

- F2 -

Dr. Foods, Inc.

Condensed Consolidated Balance Sheet

		March 31, 2022		March 31, 2021
TOTAL ASSETS	$	-	$	-
LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accrued Expenses	$	7,000	$	3,750
TOTAL LIABILITIES	$	7,000	$	3,750
Stockholders’ Equity (Deficit)
Preferred stock ($0.0001 par value, 20,000,000 shares authorized; 10,000 and 0 issued and outstanding as of March 31, 2022 and March 31, 2021, respectively)		1		-
Common stock ($0.0001 par value, 4,800,000,000 shares authorized, 2,315,276,582 and 0 issued and outstanding as of March 31, 2022 and March 31, 2021, respectively)		231,528		-
Additional paid-in capital		814,339		2,010
Accumulated deficit		(1,052,868)		(5,760)
Total Stockholders’ Equity (Deficit)		(7,000)		(3,750)
TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)	$	-	$	-

The accompanying notes are an integral part of these audited financial statements.

- F3 -

Table of Contents

Dr. Foods, Inc.

Condensed Consolidated Balance ~~Statement of Operations~~Sheets

		Year Ended March 31, 2022		For the period February 26, 2021 (Inception) to March 31, 2021
Operating Expenses
General and Administrative Expenses		1,047,108		5,760
Total Operating Expenses		1,047,108		5,760
Net Loss	$	(1,047,108)	$	(5,760)
Basic and Diluted Net Loss Per Common Share	$	(0.00)	$	-
Weighted average number of common shares outstanding- Basic and Diluted	$	2,144,009,547	$	-

(Audited)

‘		March 31, 2023		March 31, 2022
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	1,365	$	-
Accounts receivable - trade		384		-
Advance payments		567		-
Loan to related party		535,460		-
Interest Receivable - related party		4,402		-
TOTAL CURRENT ASSETS		542,178		-
TOTAL ASSETS	$	542,178	$	-

LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts payable, other	$	7,396	$	-
Accounts payable - related party		29,524		-
Accrued Expenses		2,705		7,000
Other current liabilities		497		-

TOTAL LIABILITIES	$	40,122	$	7,000

Stockholders’ Equity (Deficit)
Preferred stock ($0.0001 par value, 20,000,000 shares authorized; 10,000 issued and outstanding as of March 31, 2023 and March 31, 2022)		1		1
Common stock ($0.0001 par value, 4,800,000,000 shares authorized, 13,114,888 and 11,576,427 issued and outstanding as of March 31, 2023 and March 31, 2022, respectively)		1,312		1,158
Foreign currency translation adjustment		(23,683)		-
Additional paid-in capital		1,899,114		1,044,709
Accumulated deficit		(1,374,688)		(1,052,868)
Total Stockholders’ Equity (Deficit)		502,056		(7,000)

TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)	$	542,178	$	-

The accompanying notes are an integral part of these audited financial statements.

- F4 -

Table of Contents

Dr. Foods, Inc.

Condensed Consolidated ~~Statement~~Statements of ~~Changes in Stockholders’ Equity (Deficit)~~Operations

~~For the Period February 26, 2021~~ (~~Inception~~Audited) ~~to March 31, 2022~~

		Common Shares		Par Value Common Shares	Series Z Preferred Shares		Par Value Series Z Preferred Shares		Additional Paid-in Capital		Accumulated Deficit		Total
		Year Ended March 31, 2023		Year Ended March 31, 2022
Balances, February 26, 2021		-	$	-	-	$	-	$	-	$	-	$	-
Revenues
Expenses paid on behalf of the Company and contributed to capital		-		-	-		-		2,010		-		2,010
Revenues	$	1,000	$	-
Net loss		-		-	-		-		-		(5,760)		(5,760)
Revenues - related party		38		-
Balances, March 31, 2021		-	$	-	-		-	$	2,010	$	(5,760)	$	(3,750)
Total Revenues		1,038		-
Common shares issued after reorganization		2,315,276,582		231,528	-		-		(231,528)		-		-
Cost of revenues		-		-
Series Z preferred shares issued after reorganization		-		-	10,000		1		999,999		-		1,000,000
Gross Profit	$	1,038	$	-
Expenses paid on behalf of the Company and contributed to capital		-		-	-		-		43,858		-		43,858
Operating Expenses
Net loss		-		-	-		-		-		(1,047,108)		(1,047,108)
General and administrative expenses	$	326,423	$	1,047,108
Balances, March 31, 2022		2,315,276,582	$	231,528	10,000	$	1	$	814,339	$	(1,052,868)	$	(7,000)
Total operating expenses		326,423		1,047,108
Income (loss) from operations		(325,385)		(1,047,108)
Other income (expense)
Interest income	$	4,339	$	-
Total other income (expense)		4,339		-
Net income (loss) before tax		(321,046)		(1,047,108)
Income tax expense		(774)		-
NET INCOME (LOSS)	$	(321,820)	$	(1,047,108)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment	$	(23,683)	$	-
TOTAL COMPREHENSIVE INCOME (LOSS)	$	(345,503)	$	(1,047,108)
Income per common share
Basic	$	(0.03)	$	(0.10)
Diluted	$	-	$	-
Weighted average common shares outstanding
Basic		12,853,560		10,720,089
Diluted		-		-

The accompanying notes are an integral part of these audited financial statements.

- F5 -

Table of Contents

Dr. Foods, Inc.

~~Condensed~~ Consolidated Statement of ~~Cash~~Changes ~~Flows~~in Stockholders’ Equity (Deficit)

	Year Ended March 31, 2022			For the Period February 26, 2021 (Inception) to March 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(1,047,108)	$	(5,760)
Adjustment to reconcile net loss to net cash used in operating activities:
Preferred stock issued		1,000,000		-
Changes in current assets and liabilities:
Accrued expenses		3,250		3,750
Net cash used in operating activities		(43,858)		(2,010)
CASH FLOWS FROM FINANCING ACTIVITIES
Expenses contributed to capital	$	43,858	$	2,010
Net cash provided by financing activities		43,858		2,010
Net change in cash	$	-	$	-
Beginning cash balance		-	$	-
Ending cash balance	$	-	$	-
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	$	-	$	-
Income taxes paid	$	-	$	-

For the Period March 31, 2021 to March 31, 2023

(Audited)

	Common Shares		Par Value Common Shares	Series Z Preferred Shares		Par Value Series Z Preferred Shares		Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total

Balances, March 31, 2021	-	$	-	-	$	-	$	2,010	$	-	$	(5,760)	$	(3,750)
Common shares exchanged in merger and reorganization	11,576,427		1,158	-		-		(1,158)		-		-		-
Series Z preferred shares exchanged in merger and reorganization	-		-	10,000		1		999,999		-		-		1,000,000
Expenses paid on behalf of the Company and contributed to capital	-		-	-		-		43,858		-		-		43,858
Net loss	-		-	-		-		-		-		(1,047,108)		(1,047,108)
Balances, March 31, 2022	11,576,427	$	1,158	10,000	$	1	$	1,044,709	$	-	$	(1,052,868)	$	(7,000)
Common shares sold	1,538,461		154	-		-		769,077		-		-		769,231
Expenses paid on behalf of the Company and contributed to capital	-		-	-		-		67,574		-		-		67,574
Capital contributed by subsidiary	-		-	-		-		17,754		-		-		17,754
Net loss	-		-	-		-		-		-		(321,820)		(321,820)
Foreign currency translation	-		-	-		-		-		(23,683)		-		(23,683)
Balances, March 31, 2023	13,114,888	$	1,312	10,000	$	1	$	1,899,114	$	(23,683)	$	(1,374,688)	$	502,056

The accompanying notes are an integral part of these audited financial statements.

- F6 -

Table of Contents

Dr. Foods, Inc.

Condensed Consolidated Statements of Cash Flows

(Audited)

	Year Ended March 31, 2023			Year Ended March 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(321,820)	$	(1,047,108)
Adjustment to reconcile net loss to net cash used in operating activities:
Preferred stock issued		-		1,000,000
Changes in current assets and liabilities:
Accounts receivable		(379)		-
Advance payments		(558)		-
Accounts payable, other		29,692		-
Accounts payable, related party		7,504		-
Interest receivable		(4,338)		-
Accrued expenses		(4,234)		3,250
Other current liabilities		505		-
Net cash used in operating activities		(293,628)		(48,858)

CASH FLOWS FROM INVESTING ACTIVITIES
Loan to related party		(710,700)		-
Payments received from related party loan		183,025		-
Net cash used in investing activities		(527,675)		-

CASH FLOWS FROM FINANCING ACTIVITIES
Cash received for common shares		769,231		-
Contributed capital		85,328		43,858
Net cash provided by financing activities		854,559		43,858

Net effect of exchange rate changes on cash		(31,891)		-

Net change in cash		1,365		-
Beginning cash balance		-		-
Ending cash balance	$	1,365	$	-

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	$	-	$	-
Income taxes paid	$	-	$	-

The accompanying notes are an integral part of these audited financial statements.

- F7 -

Table of Contents

Dr. Foods, Inc.

Notes to Condensed Consolidated Financial Statements

~~Note 1 Organization and Description of Business~~(Audited)

~~Dr. Foods, Inc. (we, us, our, the "Company"~~Note or1 ~~the~~- ~~"Registrant"),~~Organization ~~formerly~~and ~~known~~Description ~~as Catapult Solutions, Inc., was incorporated in the State~~ of ~~Nevada on February 26, 2021.~~Business

OnThe Company ~~February~~was 26created for the sole purpose of participating in a Nevada holding company reorganization pursuant to NRS 92A.180, ~~2021~~NRS 92A.200, NRS ~~Jeffrey~~92A.230 ~~DeNunzio~~and ~~was appointed~~NRS ~~Chief~~92A.250. ~~Executive~~The ~~Officer~~constituent corporations in the Reorganization were Ambient Water Corporation (“AWGI” or “Predecessor”), ~~Chief~~Catapult ~~Financial~~Solutions, ~~Officer~~Inc. (“Successor”), and ~~Director~~Catapult Merger Sub, Inc. (“Merger Sub”). Our now former director, Jeffrey DeNunzio, was the sole director/officer of ~~Catapult~~each ~~Solutions~~constituent corporation in the Reorganization, ~~Inc~~which is described below.

The Company was created for the sole purpose of participating in a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250. The constituent corporations in the Reorganization were Ambient Water Corporation (“AWGI” or “Predecessor”), Catapult Solutions, Inc. (“Successor”), and Catapult Merger Sub, Inc. (“Merger Sub”). Our director is, and was, the sole director/officer of each constituent corporation in the anticipated Reorganization.

On July 20, 2021, the Company entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), White Knight Co., Ltd., a Japan Company (“WKC”), and Next Meats Holdings, Inc., a Nevada Company (“NXMH”), pursuant to which, on July 23, 2021, (“Closing Date”), CRS sold 10,000 shares of the Company’s Series Z Preferred Stock, representing , at the time, approximately 81.20% voting control of the Company; 5,000 shares of Series Z Preferred Stock were transferred to WKC and 5,000 shares of Series Z Preferred Stock were transferred to NXMH. WKC and NXMH paid consideration of three hundred seventy-five thousand dollars ($375,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with WKC and NXMH, becoming the Company’s largest controlling stockholders at the time of the transaction.

On August 24, 2021, the Company changed its name with the Nevada Secretary of State to Dr. Foods, Inc.

At this time, our wholly subsidiary, Dr. Foods Co., Ltd. has three officers, Koichi Ishizuka, Chief Executive Officer, and two Executive Officers, Iaroslav Patuk and Hideo Fujioka.

The Collaboration Agreement is for a period of two years and may be renewed thereafter under the same terms for additional one year terms unless terminated in writing, with three months’ notice, by either party. The Collaboration Agreement, amongst other things, details the terms and conditions by which Next Meats Co., Ltd. and Dr. Foods Co., Ltd. may co-develop, cooperate and contribute towards the development of new products and technologies. The specific allotment of tasks per project ~~will~~was supposed to be determined in writing by each party at the outset of collaborative efforts. To date, no specific details have been committed to writing, despite the fact that collaborative efforts have begun. It has been verbally determined that Dr. Foods Co., Ltd. will primarily, although not exclusively, contribute to research and development, and Next Meats Co., Ltd. will primarily, although not exclusively, contribute to distribution of new products/technologies. Costs pursuant to the collaborative efforts of the partners are, ~~will~~anticipated to be, the respective responsibility of the party responsible for fulfilling such tasks.

On November 3, 2021, we began trading under the symbol DRFS. The new CUSIP number associated with our common stock, as of the market effective date of November 3, 2021, is 26140D107.

On January 12, 2022, Dr. Foods, Inc., a Nevada Company, Mama Foods Co., Ltd., a Japan Company, and White Knight Co., Ltd., a Japan Company entered into a non-definitive agreement, a “Letter of Intent”, whereas it was proposed that Dr. Foods, Inc., will acquire 100% of the controlling interest of Mama Foods Co., Ltd. from White Knight Co., Ltd. in exchange for $500,000 coupled with the issuance of 19,500,000 shares of restricted Preferred Stock to White Knight Co., Ltd. The issuance of shares shall be subject to the rules and limitations set forth by the Securities Act Rule 144.

White Knight Co., Ltd. is a Japanese entity owned and controlled by Koichi Ishizuka.

Mama Foods, Co., Ltd. (“Mama Foods”) is a food company founded in Japan in 1958, currently offering customers in Japan wholesale and retail products centering on Japanese side dishes, from chilled foods to packed and sterilized food. In 2021, White Knight Co., Ltd. acquired 100% of Mama Foods from its prior controller, in exchange for approximately 1 million USD.

On March 31, 2022, Dr. Foods, Inc. and Mama Foods mutually agreed to extend the terms of the non-definitive agreement 30 more days in order to provide more time to prepare the books and records of Mama Foods Co., Ltd. This extension period had expired without the books and records of Mama Foods Co., Ltd. having been prepared or progressed in any meaningful capacity. On May 6, 2022 the parties again agreed to extend the terms of the non-definitive agreement, however this time with an expiration date of June 30, 2022, or until, if agreed upon by all parties, further notice.

The efforts to spearhead preparation of the books and records had been, and continues to be, led by Koichi Ishizuka who has outside business interests and other demands upon his time that limit his availability. It should also be noted that he does not have expertise in accounting matters. As such, the Company has engaged outside accounting expertise to assist in this process. The Company cannot state, with any level of certainty, when, or if ever, the books and records will be prepared to the satisfaction of the Issuer, and as such, when the books and records of Mama Foods Co., Ltd. will be fully audited by a PCAOB auditor.

There is a risk that the audit of Mama Foods Co., Ltd. is not completed at all, and/or that DRFS never acquires Mama Foods Co., Ltd. Even if the acquisition of Mama Foods Co., Ltd. is completed, there is the possibility that the terms of this acquisition, which is non-definitive at this time, may not be considered favorable for the company and/or its shareholders.

In February of 2022, our majority shareholders executed a resolution to ratify, affirm, and approve an amendment to our Certificate of Incorporation, increasing the authorized shares of our Common Stock from 2,400,000,000 to 4,800,000,000. The Amendment was filed with the Nevada Secretary of State on February 22, 2022, effective immediately upon filing.

Currently, we operate through Dr. Foods Co., Ltd. and DRFS Singapore and share the same business plan as that of Dr. Foods Co., Ltd. and DRFS Singapore.

The Company’s main office is located at 3F K’s Minamiaoyama 6-6-20 Minamiaoyama, Minato-ku, Tokyo 107-0062, Japan.

The Company has elected March 31st as its year end.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

This summary of significant accounting policies is presented to assist in understanding the Company's financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary to make the financial statements not misleading have been included. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly ~~liquid~~ liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents on March 31, ~~2022~~2023, and March 31, ~~2021~~2022, were $1,365 and $0, ~~for both periods~~respectively.

Revenue Recognition

The Company adopted ASC 606, Revenue from Contracts with Customers (Topic 606) (“ASC 606”), in the third quarter of fiscal year 2023, as this was the first quarter that the Company generated revenues. Under ASC 606, the Company recognizes revenue when a customer obtains control of promised goods, in an amount that reflects the consideration that the Company expects to receive in exchange for the goods. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods it transfers to the customer. Under ASC 606, disaggregated revenue from contracts with customers depicts the nature, amount, timing, and uncertainty of revenue and cash flows affected by economic factors.

Revenue from product sales

We have a performance obligation to arrange for the delivery of the goods to our customers by the suppliers we contract to manufacture the goods.

We recognize revenue when the goods are delivered by the supplier to the customer.

For our primary transaction-based revenue sources, a net presentation (i.e., amounts billed to customers less amounts paid to suppliers) as suppliers are primarily responsible for providing the underlying revenue. is appropriate for most of our earnings transactions. We do not control the goods that our suppliers offer to our customers.

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of March 31, 2023 and 2022, the Company had no deferred revenues related to product sales.

Revenue – related party

During the period ended March 31, 2023, revenue totaling approximately $38 was recognized from sales to related party WB Burgers Japan Co. Ltd. (hereinafter referred to as “WBBJ”). WBBJ is considered as a related party due to the fact that Koichi Ishizuka, CEO of the Company, indirectly controls WBBJ through his share ownership of WB Burgers Asia, Inc. The terms and conditions applied to the above transactions were the same as those applied to sales to customers not related to the Company.

The Company’s revenue consists of food product sales through its subsidiary, Dr. Foods Co., Ltd.

Income Taxes

The Company accounts for income taxes ~~under~~ under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized on March 31, 2023 and 2022.

Basic Earnings (Loss) Per Share

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

The Company does not have any potentially dilutive instruments as of March 31, ~~2022,~~2023 and, thus, anti-dilution issues are not applicable.

Fair Value of Financial Instruments

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, ~~2022~~2023. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued expenses.

- F7F8 -

Table of Contents

Related Parties

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Share-Based Compensation

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

The Company had no stock-based compensation plans as of March 31, ~~2022~~2023, and March 31, ~~2021~~2022.

The Company’s stock-based ~~compensation~~ compensation for the periods ended March 31, ~~2022,~~2023 and March 31, ~~2021,~~2022 was $0 and $1,000,000 ~~and $0~~, respectively.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 is amended by ASU 2018-01, ASU2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01, which FASB issued in January 2018, July 2018, July 2018, December 2018 and March 2019, respectively (collectively, the amended ASU 2016-02). The amended ASU 2016-02 requires lessees to recognize on the balance sheet a right-of-use asset, representing its right to use the underlying asset for the lease term, and a lease liability for all leases with terms greater than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from current GAAP. The amended ASU 2016-02 retains a distinction between finance leases (i.e. capital leases under current GAAP) and operating leases. The classification criteria for distinguishing between finance leases and operating leases will be substantially similar to the classification criteria for distinguishing between capital leases and operating leases under current GAAP. The amended ASU 2016-02 also requires qualitative and quantitative disclosures designed to assess the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is permitted to be used when an entity adopts the amended ASU 2016-02, which includes a number of optional practical expedients that entities may elect to apply.

We have no assets and or leases and do not believe we will be impacted in the foreseeable future by the newly adopted accounting standard(s) mentioned above.

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note 3 - Going Concern

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

The Company demonstrates adverse conditions that raise substantial doubt about the Company's ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

The Company has not established ~~any source~~sufficient of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is is no assurance that management's plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

Note 4 - Income Taxes

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of March 31, ~~2022~~2023, the Company has incurred a net loss of approximately $1,~~052~~374,~~868~~ 688 which resulted in a net operating loss for income tax purposes. The loss results in a deferred tax asset of approximately $~~221~~288,~~102~~ 684 at the effective statutory rate of 21%. The deferred tax asset has been offset by an equal valuation allowance. Given our inception on February 26, 2021, and our fiscal year end of March 31, ~~2022~~2023, we have completed ~~only~~three ~~two~~ taxable fiscal years.

~~Note~~Potential 5benefits ~~Commitments~~of ~~and~~income ~~Contingencies~~tax losses are not recognized in the accounts until realization is more likely than not. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company has incurred a net operating loss carryforward of $1,374,688 which begins expiring in 2036. The Company has adopted ASC 740, “Accounting for Income Taxes”, as of its inception. Pursuant to ASC 740 the Company is required to compute tax asset benefits for non-capital losses carried forward. The potential benefit of the net operating loss has not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the loss carried forward in future years.

~~The~~Significant ~~Company~~components ~~follows~~of ~~ASC~~the ~~450-20,~~Company’s ~~Loss Contingencies, to~~deferred ~~report~~tax ~~accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources~~ assets are ~~recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies~~ as ~~of March 31, 2022 other than the below~~follows:

	March 31,

	2023		2022
Deferred tax asset, generated from net operating loss	$	288,684	$	222,102
Valuation allowance		(288,684)		(222,102)
	$	—	$	—

The reconciliation of the effective income tax rate to the federal statutory rate is as follows:

Federal income tax rate 21.0%	21.0	%
Increase in valuation allowance (21.0%)	(21.0	%)
Effective income tax rate 0.0%	0.0	%

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carryforwards may be limited as to use in future years

Note 5 - Commitments and Contingencies

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of March 31, 2023 other than the below:

The Collaboration Agreement is for a period of two years and may be renewed thereafter under the same terms for additional one-year terms unless terminated in writing, with three months’ notice, by either party. The Collaboration Agreement, amongst other things, details the terms and conditions by which Next Meats Co., Ltd. and Dr. Foods Co., Ltd. may co-develop, collaborate and contribute towards the development of new products and technologies. The specific allotment of tasks per project will be determined in writing by each party at the outset of collaborative efforts. Dr. Foods Co., Ltd. will primarily, although not exclusively, contribute to research and development, and Next Meats Co., Ltd. will primarily, although not exclusively, contribute to distribution of new products and technologies. Costs pursuant to the collaborative efforts of the partners, will be the respective responsibility of the party responsible for fulfilling such tasks.

Dr. Foods Co., Ltd. intends to conduct research and development of new food products pursuant to the Collaboration Agreement ~~via its three new executive officers, all of whom were appointed to Dr~~. ~~Foods Co., Ltd. on October 11th of 2021.~~

On January 12, 2022, Dr. Foods, Inc., Mama Foods Co., Ltd. (“Mama Foods”), a Japan Company, and White Knight Co., Ltd. (“WKC”) entered into a non-definitive agreement, a “Letter of Intent”, whereas it is proposed that Dr. Foods, Inc., will acquire 100% of the controlling interest of Mama Foods from WKC in exchange for $500,000 coupled with the issuance of 19,500,000 shares of restricted Preferred Stock to WKC. The issuance of shares shall be subject to the rules and limitations set forth by the Securities Act Rule 144. Mama Foods is a food company founded in Japan in 1958, currently offering customers in Japan wholesale and retail products centering on Japanese side dishes, from chilled foods to packed and sterilized food. Mama Foods uses ingredients carefully taken from natural kelp and bonito without adding any chemical seasonings, preservatives, coloring agents, etc. Mama Foods has two existing “in house” production facilities and produces 100% of its current product offerings. From time to time, it also produces products of other third parties, including certain products offered for sale by Next Meats Co., Ltd., such as “Next Kalbi 2.0”, a boneless short rib made from meat substitutes. Currently, Mama Foods employs approximately 4344 individuals. In 2021, WKC. acquired 100% of Mama Foods from its prior controller, in exchange for approximately 1 million USD.

The terms of the aforementioned non-definitive agreement may change given the non-definitive agreement is not definitive in nature.

Note 6 - Shareholder Equity

Preferred Stock

The authorized preferred stock of the Company consists of 20,000,000 shares with a par value of $0.0001. There were 10,000 Series Z Preferred Stock and 0 shares of preferred stock issued and outstanding as of March 31, ~~2022~~2023, and March 31, ~~2021~~2022, respectively. Series Z Preferred Stock has no conversion rights to any other class, and every vote of Series Z Preferred Stock has voting rights equal to 1,000,000 votes of Common Stock.

At the time of the reorganization, ~~April 28, 2021,~~ 10,000 shares of Series Z Preferred Stock were converted and exchanged for preferred shares of Dr. Foods, Inc. The shares issued toand outstanding at the time by CRS Consulting, LLC, ~~for~~were ~~services~~originally ~~rendered~~issued tofor ~~the~~services ~~Company~~rendered.

On July 20, 2021, the Company entered into a Share Purchase Agreement (the “Agreement”) by and among CRS, White Knight Co., Ltd., a Japan Company (“WKC”), and Next Meats Holdings, Inc., a Nevada Company (“NXMH”), pursuant to which, CRS sold 10,000 shares of the Company’s Series Z Preferred Stock, representing approximately, at the time, 81.20% voting control of the Company; 5,000 shares of Series Z Preferred Stock were transferred to WKC and 5,000 shares of Series Z Preferred Stock were transferred to NXMH (see Note 1).

Common Stock

The authorized common stock of the ~~Company~~ Company consists of 4,800,000,000 shares with a par value of $0.0001. There were 213,~~315~~114,~~276,582~~888 and 011,576,427 shares of of common stock issued and outstanding as of March 31, ~~2022~~2023, and March 31, ~~2021~~2022, respectively.

At the time of reorganization, April 28, 2021, former shareholders of Ambient Water Corporation became shareholders of Catapult Solutions, Inc., representing all the common ~~shares~~ shares outstanding at that time.

On or about May 31, 2022, we sold 1,538,461 shares of restricted Common Stock to SJ Capital Co., Ltd., a Japanese Company, for proceeds totaling approximately $769,231.

On September 21, 2022, the Company completed a reverse stock split whereas every 200 shares of the Company’s issued and outstanding common stock were automatically converted into one issued and outstanding share of common stock, without any change in the par value per share. Immediately prior to the Stock Split, we had 2,622,968,890 shares of Common Stock issued and outstanding. Immediately following September 21, 2022, we had 13,114,888 shares of Common Stock issued and outstanding (see Note 1). These financial reports reflect the 200 to 1 reverse stock split for all periods for comparative purposes.

Additional Paid-In Capital

The Company’s sole officer and Director, Koichi Ishizuka, paid expenses on behalf of the company and its wholly owned subsidiary totaling $3685,~~758~~ 328 during the ~~period~~year ended March 31, ~~2022~~2023. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

The Company’s ~~former~~ sole officer and ~~director~~Director, ~~Jeffrey~~Koichi ~~DeNunzio~~Ishizuka, paid expenses on behalf of the ~~company~~Company and its wholly owned subsidiary totaling $736,~~100~~ 758 during the period ended March 31, 2022. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $27,~~010~~100 during the period ended March 31, ~~2021~~2022. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

~~The~~Note ~~$9,110 in~~7 ~~total~~– ~~payments~~Related ~~are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.~~Party

Note 7 ~~Subsequent Events~~Receivable

OnDuring orthe ~~about~~period ~~May~~ended March 31, ~~2022, we sold~~ ~~307~~2023,~~692,308~~ ~~shares~~the ofCompany ~~restricted~~loaned ~~Common~~approximately ~~Stock~~$721,186 to SJrelated ~~Capital~~party White Knight Co., Ltd (“White Knight”). White Knight is controlled by our sole director, aKoichi ~~Japanese~~Ishizuka. ~~Company~~During this same period, atthe aWhite ~~price~~Knight ofrepaid approximately $0185,726 to the Company.~~0025~~ ~~USD~~In ~~per~~addition, loan ~~share~~interest oftotaling ~~Common~~approximately $7,493 was accrued on the loan and is payable by White Knight to the Company. This note receivable ~~Stock~~from White Knight is planned to be part of the consideration for the future planned acquisition of Mama Foods Co., Ltd.

Accounts payable

During the period ended March 31, 2023, related party White Knight and our sole officer and director invoiced the Company for expenses paid on the behalf of the Company totaling approximately $29,524.

Additional paid-in capital

Note 8 - Subsequent Events

On or about June 26, 2023, the company consummated an agreement for the sale of 593,811 shares of restricted Common Stock to Ultimate One LLC, a Japanese Company, at a price of $0.315 per share of Common Stock. The transaction was completed, and recorded by the Company’s transfer agent, on June 30, 2023. The total subscription amount paid by Ultimate One LLC was approximately $187,050. Ultimate One LLC is not a related party to the Company.

The proceeds from this sale are to be used by the Company for working capital.

The aforementioned sale of shares was conducted pursuant to Regulation S of the Securities Act of 1933, as amended ("Regulation S"). The sale of shares was made only to non-U.S. persons/entities (as defined under Rule 902 section (k)(2)(i) of Regulation S), pursuant to offshore transactions, and no directed selling efforts were made in the United States by the issuer, a distributor, any of their respective affiliates, or any person acting on behalf of any of the foregoing.

- F8F9 -

Table of Contents

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Disclosure Controls and Procedures

The Company has adopted and maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this annual report, is collected, recorded, processed, summarized and reported within the time periods specified in the rules of the SEC. The Company’s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule 13a-15, the Company’s management, including the Chief Executive Officer who also serves as our Principal Financial Officer, has conducted an evaluation of the effectiveness of disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Office who also serves as our Principal Financial Officer concluded that the disclosure controls and procedures are ineffective.

Our Chief Executive Officer, Koichi Ishizuka, has reviewed the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) as of the end of the period covered by the report March 31, ~~2022~~2023 and has concluded that (i) the Company’s disclosure controls and procedures are not effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Commission, and (ii) the Company’s controls and procedures have not been designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

~~Management’s Report~~Evaluation onof ~~Internal~~disclosure ~~Control~~controls ~~over Financial Reporting~~and procedures.

~~The Company’s~~Our management, iswith the ~~responsible~~participation ~~for~~of ~~establishing~~Koichi ~~and~~Ishizuka, ~~maintaining~~our ~~adequate~~Chief ~~internal~~Executive ~~control~~Officer, ~~over~~who ~~financial~~also ~~reporting,~~serves as ~~defined in~~our ~~Exchange~~Chief ~~Act~~Financial ~~Rule~~Officer, ~~13a-15(f).~~evaluated ~~The~~the ~~Company’s~~effectiveness of ~~internal~~our ~~control~~disclosure ~~over~~controls ~~financial~~and ~~reporting~~procedures ispursuant ~~designed~~ to ~~provide~~Rule ~~reasonable~~13a-15 ~~assurance to~~under the ~~Company’s~~Exchange ~~management~~Act. ~~and~~In ~~board~~designing ofand ~~directors~~evaluating ~~regarding~~ the ~~preparation~~disclosure controls and ~~fair~~procedures, ~~presentation~~management ofrecognizes ~~published~~that ~~financial~~any ~~statements. Management~~controls ~~conducted~~and anprocedures, ~~assessment~~no ofmatter ~~the~~how ~~Company’s~~well ~~internal~~designed ~~control~~and ~~over~~operated, ~~financial~~can ~~reporting~~provide ~~based~~only ~~on the framework and criteria~~reasonable ~~established~~assurance byof achieving the ~~Committee~~desired ofcontrol ~~Sponsoring~~objectives. ~~Organizations~~In ofaddition, the ~~Treadway~~design ~~Commission~~of indisclosure ~~Internal~~controls ~~Control~~and –procedures ~~Integrated~~must ~~Framework~~reflect the ~~issued~~fact inthat ~~2013.~~there ~~Based~~are onresource ~~the assessment~~constraints, ~~management~~and ~~concluded~~ that, asmanagement ofis ~~March~~required 31to ~~2022,~~apply ~~the~~its ~~Company’s~~judgment ~~internal~~in ~~control~~evaluating ~~over~~the ~~financial~~benefits of possible ~~reporting~~controls isand ~~ineffective~~procedures ~~based~~relative onto ~~those~~their ~~criteria~~costs.

~~The Company’s~~Based on management’s evaluation, ~~including~~Koichi ~~its~~Ishizuka, ~~Chief Executive Officer~~ who ~~also~~ serves as our Chief ~~Financial~~Executive Officer, ~~does not expect that the Company’s disclosure controls~~ and ~~procedures~~Chief ~~and~~Financial ~~its internal control processes will prevent all error and all fraud. A control system~~Officer, noconcluded ~~matter how well conceived and operated~~that, ~~can~~as ~~provide~~a ~~only~~result ~~reasonable, not absolute, assurance that the objectives~~ of the ~~control~~ ~~system~~material ~~are~~weaknesses ~~met.~~described ~~Further~~below, ~~the~~our ~~design~~disclosure ofcontrols aand ~~control~~procedures ~~system~~are ~~must~~not ~~reflect~~designed ~~the~~at ~~fact~~a ~~that~~reasonable ~~there~~assurance ~~are~~level ~~resource constraints,~~ and ~~the~~are ~~benefits of~~ineffective ~~controls must be considered relative~~ to ~~their costs. Because of the inherent limitations in all control systems, no evaluation of controls can~~ provide ~~absolute~~reasonable assurance that ~~all~~information ~~control~~we ~~issues~~are ~~and~~required ~~instances~~to ofdisclose ~~error~~in orreports ~~fraud, if any, within the Company have been detected. These inherent limitations include the realities~~ that ~~judgments~~we infile ~~decision-making~~or ~~can~~submit beunder ~~faulty, and that~~ the ~~breakdowns~~Exchange ~~can occur because~~Act ofis ~~simple error or mistake. Additionally~~recorded, ~~controls can be circumvented by the individual acts of some persons~~processed, ~~by collusion of two or more people~~summarized, orand byreported ~~management~~within ~~override of~~ the ~~control.~~time ~~The~~periods ~~design~~specified ~~of any system of controls also is based~~ in ~~part~~SEC ~~upon~~rules ~~certain~~and ~~assumptions about the likelihood of future events~~forms, and ~~there can be no assurance~~ that ~~any~~such ~~design~~information ~~will succeed in achieving its stated goals under~~is ~~all~~accumulated ~~potential~~and ~~future~~communicated ~~conditions.~~to ~~Over~~our ~~time~~management, ~~controls~~including ~~may~~our ~~become~~chief ~~inadequate~~executive ~~because~~officer ofand ~~changes~~chief infinancial ~~conditions~~officer, oras ~~the~~appropriate, ~~degree of compliance~~to ~~with~~allow ~~the~~timely ~~policies~~decisions orregarding ~~procedures~~required ~~may deteriorate~~disclosure. ~~Because~~The ofmaterial ~~the~~weaknesses, ~~inherent~~which ~~limitations~~relate into ainternal ~~cost-effective~~ control ~~system,~~over ~~misstatements due to error or fraud may occur and may not be detected. However, these inherent limitations are known features of the~~ financial reporting, ~~process.~~that ~~Therefore,~~were itidentified ~~is possible to design into the process safeguards to reduce, though not eliminate, this risk.~~are:

~~The matters~~a) ~~involving~~Due ~~internal~~to ~~controls~~our ~~and~~small ~~procedures~~size, ~~that~~we ~~our~~did ~~Chief~~not ~~Executive~~have ~~Officer~~sufficient ~~considered~~personnel toin beour ~~material~~accounting ~~weaknesses~~and ~~under~~financial ~~the~~reporting ~~standards of~~functions. ~~the~~As ~~Committee~~a ofresult, ~~Sponsoring~~we ~~Organizations~~were ofnot ~~Treadway~~able ~~Commission~~to ~~were:~~achieve ~~domination~~adequate segregation of ~~management~~duties byand awere ~~single~~not ~~individual~~able ~~without~~to ~~adequate compensating~~provide ~~controls,~~for ~~lack~~adequate review of athe ~~majority~~financial ofstatements. ~~outside~~This ~~directors~~control ondeficiency, ~~board~~which ofis ~~directors~~pervasive in nature, ~~inadequate~~results ~~segregation~~in ofa ~~duties~~reasonable ~~consistent~~possibility ~~with control~~that ~~objectives,~~material ~~lack~~misstatements of ~~well-established~~the ~~procedures~~consolidated tofinancial ~~identify,~~statements ~~approve~~will ~~and~~not ~~report~~be ~~related~~prevented ~~party~~or ~~transactions,~~detected ~~and~~on ~~lack~~a oftimely anbasis; ~~audit committee.~~and

~~Management~~b) ~~believes~~We ~~that~~lacked ~~the~~sufficient ~~material~~written ~~weaknesses~~policies ~~did~~and ~~not~~procedures ~~have~~for anaccounting ~~effect~~and ~~on our~~ financial ~~results.~~reporting ~~However,~~with respect ~~management~~to ~~believes that~~ the ~~lack~~requirements ~~of a functioning audit committee~~ and ~~inadequate~~application ~~segregation~~ of ~~duties~~U.S. ~~results~~GAAP ~~in ineffective oversight in the establishment~~ and ~~monitoring of~~SEC ~~required~~disclosure ~~internal~~requirements ~~controls~~ and ~~procedures,~~the ~~which~~approval ~~could~~of ~~result~~related inparty ~~a material misstatement in our financial statements in future periods~~transactions.

~~Management recognizes~~We ~~that~~also ~~its~~intend ~~controls~~to create written policies and procedures ~~would~~for beaccounting ~~substantially~~and ~~improved~~financial ifreporting wewith ~~had~~respect anto ~~audit~~the ~~committee~~requirements and ~~two~~application ~~individuals~~of ~~serving as~~U.S. ~~officers~~GAAP and SEC asdisclosure ~~such~~requirements isin ~~actively~~the ~~seeking to remediate this issue~~future.

We will continue to monitor and evaluate the effectiveness of our disclosure controls and procedures and our internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

Management’s Remediation Initiatives

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:

We will create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. And, we plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us.

Management believes that the appointment of one or more outside directors, who shall be appointed to a fully functioning audit committee, will remedy the lack of a functioning audit committee and a lack of a majority of outside directors on our Board.

We will work as quickly as possible to implement these initiatives; however, the lack of adequate working capital and positive cash flow from operations will likely slow this implementation.

Changes in Internal Control

There have been no changes in internal controls over the financial reporting that occurred during the fiscal quarter ended March 31, ~~2022~~2023, that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report.

Item 9B. Other Information.

None.

- 9 -

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Mr. Koichi Ishizuka, Age 5052 - Chief Executive Officer, Chief Financial Officer, President, Director, Secretary, and Treasurer

Background of Mr. Koichi Ishizuka

~~In 2004~~ Mr. Koichi Ishizuka attended ~~graduated with his MBA from~~ the University of Aoyama Gakuin where he received his MBA in 2004. Several years later in 2011 he graduated from the Advanced ~~Management~~ Management Program at Harvard School of Business. Following Mr. Ishizuka’s formal education, he took a position as the head of marketing with Thomson Reuters, a mass media and information firm. Thereafter, he served as the CEO of Xinhua Finance Japan in 2006, Fate Corporation in 2008, and LCA Holdings., Ltd in 2009. Currently, Mr. Ishizuka serves as the Chief Executive Officer of OFF Line Co., Ltd., Photozou Co., Ltd., Photozou Holdings, Inc., ~~and~~ Photozou Koukoku Co., Ltd., Off Line International, Inc. and OFF Line Japan Co., Ltd. He has held the position of CEO with OFF Line Co., Ltd. ~~Since~~since 2013, Photozou Co., Ltd since 2016, Photozou Holdings, Inc since 2017 ~~and~~ , Photozou Koukoku Co., Ltd. since 2017, Zentrum Holdings, Inc. (formerly known as Off Line International, Inc.) since 2019 and OFF Line Japan Co., Ltd. ~~manages~~ since 2018. On November 18, 2020 he was appointed as Chief Financial Officer and ~~operates~~Director, aand ~~Japanese~~on ~~communication~~December ~~application~~28, ~~named~~2021 he was appointed Chief Executive Officer, ~~“AirTalk~~of Next Meats Holdings, Inc.”; ~~This~~he holds both positions to this date. Koichi Ishizuka also has an equity interest in Next Meats Holdings, Inc. Koichi Ishizuka is ~~Off~~also ~~Line~~Chief Financial Officer of Next Meats Co., Ltd.’s, ~~primary~~a ~~business~~Japanese ~~activity.~~alternative Inmeat ~~June~~company. ~~2018~~Since its inception on April 14, he2021, ~~incorporated~~Koichi ~~OFF~~Ishizuka ~~Line~~has served as CEO of WB Burgers Japan Co., Ltd., a ~~Japan~~Japanese ~~corporation~~Company. On ~~November~~May 227, ~~2019~~2021, heMr. ~~incorporated~~Koichi ~~OFF~~Ishiukza ~~Line~~was ~~International~~appointed as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director of Business Solutions Plus, Inc., awhich ~~Delaware~~is ~~corporation~~now known as WB Burgers Asia, Inc. On ~~November~~July 1823, ~~2020~~2021, ~~Koichi~~Mr. Ishizuka ~~became~~was ~~the~~appointed as Chief Executive Officer, Chief Financial Officer, President, Treasurer and Director of ~~Next~~Dr. ~~Meats~~Foods, ~~Holdings~~Inc. (formerly known as Catapult Solutions, Inc.). On March 21, ~~where~~2022, Mr. Ishizuka was appointed as the Chief Executive Officer, Chief Financial Officer, President, Secretary, heTreasurer, ~~remains~~and toDirector ~~this~~of ~~date~~Perfect Solutions Group, Inc.

As of the date of this filing, there has not been any material plan, contract or arrangement (whether or not written) to which our sole officer and director are a party in connection with their appointments at Dr. Foods, Inc.

Employees

AsCurrently, we, “Dr. ofFoods, ~~March~~Inc.”, 31have only one employee, ~~2022~~our sole officer and Director Koichi Ishizuka, wewho ~~had no~~is not compensated at present for his services. However, pursuant to an arrangement with Next Meats Co., Ltd., a Japan Corporation, Next Meats Co., Ltd. provides temporary employees (staff) ~~outside~~to our Company as needed to further our business agenda. Regarding this arrangement, we are billed by Next Meats Co. Ltd. on a case by case basis depending on the amount of staff and hours allocated by each staff member to our ~~sole~~business ~~officer~~endeavors, primarily consisting of research and ~~director~~development.

Director’s Term of Office

Directors will hold office until the next annual meeting of stockholders and the election and qualification of their successors. Officers are elected annually by our board of directors and serve at the discretion of the board of directors. Presently, we have a single director, Koichi Ishizuka.

Corporate Governance

The Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with the Securities and Exchange Commission (the “SEC”) and in other public communications made by the Company; and strives to be compliant with applicable governmental laws, rules and regulations. The Company has not formally adopted a written code of business conduct and ethics that governs the Company’s employees, officers and Directors as the Company is not required to do so.

In lieu of an Audit Committee, the Company’s Board of Directors, is responsible for reviewing and making recommendations concerning the selection of outside auditors, reviewing the scope, results and effectiveness of the annual audit of the Company's financial statements and other services provided by the Company’s independent public accountants. Our sole officer and director review the Company's internal accounting controls, practices and policies.

Committees of the Board

Our Company currently does not have nominating, compensation, or audit committees or committees performing similar functions nor does our Company have a written nominating, compensation or audit committee charter. Our Director believes that it is not necessary to have such committees, at this time, because the Director can adequately perform the functions of such committees.

Audit Committee Financial Expert

Our Board has determined that we do not have a board member that qualifies as an “audit committee financial expert” as defined in Item 407(D)(5) of Regulation S-K, nor do we have a Board member that qualifies as “independent” as the term is used in Item 7(d)(3)(iv)(B) of Schedule 14A under the Securities Exchange Act of 1934, as amended, and as defined by Rule 4200(a)(14) of the FINRA Rules.

We believe that our Director is capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. The Director of our Company does not believe that it is necessary to have an audit committee because management believes that the Board of Directors can adequately perform the functions of an audit committee. In addition, we believe that retaining an independent Director who would qualify as an "audit committee financial expert" would be overly costly and burdensome and is not warranted in our circumstances given the stage of our development and the fact that we have not generated any positive cash flows from operations to date.

Involvement in Certain Legal Proceedings

Our sole officer and director have not been involved in any of the following events during the past ten years:

1.	bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
2.	any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
3.	being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his/her involvement in any type of business, securities or banking activities; or
4.	being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.
5.	Such person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;
6.	Such person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;
7.	Such person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:(i) Any Federal or State securities or commodities law or regulation; or(ii) Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or(iii) Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
8.	Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Independence of Directors

We are not required to have independent members of our Board of Directors, and do not anticipate having independent Directors until such time as we are required to do so.

Code of Ethics

We have not adopted a formal Code of Ethics. The Board of Directors evaluated the business of the Company and the number of employees and determined that since the business is operated by a small number of persons, general rules of fiduciary duty and federal and state criminal, business conduct and securities laws are adequate ethical guidelines. In the event our operations, employees and/or Directors expand in the future, we may take actions to adopt a formal Code of Ethics.

Shareholder Proposals

Our Company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for Directors. The Board of Directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum criteria for the election of nominees to the Board of Directors and we do not have any specific process or procedure for evaluating such nominees. The Board of Directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

A shareholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed to our President, at the address appearing on the first page of this Registration Statement.

- 10 -

Table of Contents

Item 11. Executive Compensation.

Summary Compensation Table

Name and principal position (a)	As of March 31, (b)	Salary ($) (c)	Bonus ($) (d)	Stock Awards ($) (e)	Option Awards ($) (f)	Non-equity incentive plan compensation ($) (g)	Non-qualified deferred compensation earnings ($) (h)	All other compensation ($) (i)	Total ($) (j)
Jeffrey DeNunzio, Former Sole Officer and Director	~~2021~~2022	-	-	-	-	-	-	-	-
	2022	-	-	-	-	-	-	-	-
	2023	-	-	-	-	-	-	-	-
Koichi Ishizuka, Sole Officer and Director	~~2021~~2022	-	-	-	-	-	-	-	-
	2022	-	-	-	-	-	-	-	-
	2023	-	-	-	-	-	-	-	-

Summary of Compensation

Stock Option Grants

We have not granted any stock options to our executive officers since our incorporation.

Employment Agreements

We do not have an employment or consulting agreements with any officer or Director.

Compensation Discussion and Analysis

Director Compensation

Our Board of Directors does not currently receive any consideration for their services as members of the Board of Directors. The Board of Directors reserves the right in the future to award the members of the Board of Directors cash or stock based consideration for their services to the Company, which awards, if granted shall be in the sole determination of the Board of Directors.

Executive Compensation Philosophy

Our Board of Directors determines the compensation given to our executive officers in their sole determination. Our Board of Directors reserves the right to pay our executive or any future executives a salary, and/or issue them shares of common stock issued in consideration for services rendered and/or to award incentive bonuses which are linked to our performance, as well as to the individual executive officer’s performance. This package may also include long-term stock based compensation to certain executives, which is intended to align the performance of our executives with our long-term business strategies. Additionally, while our Board of Directors has not granted any performance base stock options to date, the Board of Directors reserves the right to grant such options in the future, if the Board in its sole determination believes such grants would be in the best interests of the Company.

Incentive Bonus

The Board of Directors may grant incentive bonuses to our executive officer and/or future executive officers in its sole discretion, if the Board of Directors believes such bonuses are in the Company’s best interest, after analyzing our current business objectives and growth, if any, and the amount of revenue we are able to generate each month, which revenue is a direct result of the actions and ability of such executives.

Long-term, Stock Based Compensation

In order to attract, retain and motivate executive talent necessary to support the Company’s long-term business strategy we may award our executive and any future executives with long-term, stock-based compensation in the future, at the sole discretion of our Board of Directors, which we do not currently have any immediate plans to award.

- 11 -

Table of Contents

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

As of ~~the~~August ~~date~~16, ~~of this report~~2023, the Company has 213,~~622~~708,~~968,890~~699 shares of common stock issued and outstanding, which number of issued and outstanding shares of of common stock have been used throughout this report. The below table is as of August 16, 2023.

Name and Address of Beneficial Owner	Shares of Common Stock Beneficially Owned	Common Stock Voting Percentage Beneficially Owned	Voting Shares of Preferred Stock	Preferred Stock Voting Percentage Beneficially Owned	Total Voting Percentage Beneficially Owned ~~(1)~~
Executive Officers and Directors
Koichi Ishizuka 1 3F K’s Minamiaoyama 6-6-20-Minamiaoyama, Minato-ku Tokyo, Japa	0	0%	10,000	100%	90.34%
Koichi Ishizuka 1 3F K’s Minamiaoyama 6-6-20-Minamiaoyama, Minato-ku Tokyo, Japan	0	0%	10,000	100%	99.86%
5% or Greater Shareholders
White Knight Co., Ltd. 1 3F K’s Minamiaoyama 6-6-20-Minamiaoyama, Minato-ku Tokyo, Japan	0	0%	10,000	100%	9099.3486%
SJ Capital Co., Ltd. 3-1-9, Kawara-machi, Chuo-ku, Osaka, Japan	~~307~~1,~~692~~538,~~308~~462	11.7322%	0	0%	900.3400%

1 Koichi Ishizuka is our sole officer, and director as of the date of this report. He also owns and controls White Knight Co., Ltd., a Japan entity. Via his ownership and control of White Knight Co., ~~which~~Ltd., Koichi Ishizuka is ~~our~~the ~~current~~beneficial ~~controlling~~owner ~~shareholder~~of 10,000 shares of Series Z Preferred Stock. Series Z Preferred Stock has no conversion rights to any other class, and every vote of Series Z Preferred Stock has voting rights equal to 1,000,000 votes of Common Stock.

~~Beneficial~~* Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, ~~upon~~ upon exercise of an option or warrant) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following table does not necessarily reflect the person’s actual voting power at any particular date.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

~~The Company’s~~Additional sole officer and Director, Koichi Ishizuka, paid expenses on behalf of the company and its wholly owned subsidiary totaling $36,758 during the period ended March 31, 2022. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paidPaid-inIn ~~capital.~~Capital

The Company’s ~~former~~ sole officer and ~~director~~Director, ~~Jeffrey~~Koichi ~~DeNunzio~~Ishizuka, paid expenses on behalf of the company ~~totaling~~and its wholly owned subsidiary totaling $767,~~100~~574 during the ~~period~~year ended March 31, ~~2022~~2023. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

The Company’s ~~former~~ sole officer and ~~director~~Director, ~~Jeffrey~~Koichi ~~DeNunzio~~Ishizuka, paid expenses on behalf of the ~~company~~Company ~~totaling~~and its wholly owned subsidiary totaling $236,~~010~~ 758 during the period ended March 31, ~~2021~~2022. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

The Company’s former sole officer and director, Jeffrey DeNunzio, paid expenses on behalf of the company totaling $97,~~110~~100 induring ~~total~~the period ended March 31, 2022. These payments are considered contributions to the company with no expectation of repayment and are posted as additional paid-in capital.

~~For~~Office ~~the year ended March 31, 2022 and 2021, the Company rented office space and storage space from the Company’s officer free of charge.~~Space

We utilize the office space and equipment of Next Meats Co., Ltd., as well as office space of our management, at no cost. Management estimates such amounts to be immaterial.

Sale of Stock

On or about May 31, 2022, we sold 1,538,462 shares of restricted Common Stock to SJ Capital Co., Ltd., a Japanese Company, for proceeds totaling approximately $769,231. The price paid per share of restricted Common Stock was approximately $0.50 per share. We believe SJ Capital Co., Ltd. may be deemed to be a related party as they hold over 10% of the shares of our class of Common Stock.

The proceeds from this sale are to be used by the Company for working capital.

Collaborative Agreement

Next Meats Co., Ltd. is a wholly owned subsidiary of Next Meats Holdings, Inc., a Nevada Corporation. Koichi Ishizuka is Chief Executive Officer, Chief Financial Officer, President, Secretary, and Director of Next Meats Holdings, Inc.

Other Information

On January 12, 2022, Dr. Foods, Inc., a Nevada Company, Mama Foods Co., Ltd., a Japan Company, and White Knight Co., Ltd., a Japan Company entered into a non-definitive agreement, a “Letter of Intent”, whereas it was proposed that Dr. Foods, Inc., will acquire 100% of the controlling interest of Mama Foods Co., Ltd. from White Knight Co., Ltd. in exchange for $500,000 coupled with the issuance of 19,500,000 shares of restricted Preferred Stock to White Knight Co., Ltd. The issuance of shares shall be subject to the rules and limitations set forth by the Securities Act Rule 144. The terms of this non-definitive agreement may be subject to change.

On March 31, 2022, Dr. Foods, Inc. and Mama Foods mutually agreed to extend the terms of the non-definitive agreement 30 more days in order to provide more time to prepare the books and records of Mama Foods Co., Ltd. This extension period expired without the books and records of Mama Foods Co., Ltd. having been prepared or progressed in any meaningful capacity. On May 6, 2022 the parties again agreed to extend the terms of the non-definitive agreement, however this time with an expiration date of June 30, 2022, or until, if agreed upon by all parties, further notice.

Mama Foods, Co., Ltd. (“Mama Foods”) is a food company founded in Japan in 1958, currently offering customers in Japan wholesale and retail products centering on Japanese side dishes, from chilled foods to packed and sterilized food. Mama Foods uses ingredients carefully taken from natural kelp and bonito without adding any chemical seasonings, preservatives, coloring agents, etc. Mama Foods has two existing “in house” production facilities and produces 100% of its current product offerings. From time to time, it also produces products of other third parties, including certain products offered for sale by Next Meats Co., Ltd., such as “Next Kalbi 2.0”, a boneless short rib made from meat substitutes. Currently, Mama Foods employs approximately 44 individuals. In 2021, White Knight Co., Ltd. acquired 100% of Mama Foods from its prior controller, in exchange for approximately 1 million USD. The current website for Mama Foods, which includes additional information, can be found here: mama-foods.com/en/

Currently, the Company is pending moving forward with the acquisition of Mama Foods Co., Ltd. as Mama Foods Co., Ltd. has yet to complete a PCAOB audit of its financial statements for the last two fiscal years.

At this time, the audit of Mama Foods Co., Ltd. is actively taking place by M&K CPAS, PLLC (“M&K”). However, we understand that progress has been minimal. The exchange of information between Mama Foods Co., Ltd. and M&K has been spearheaded by Koichi Ishizuka, who has minimal time, resources, and expertise to expedite such a process. Koichi Ishizuka has also engaged the services of an accounting professional to better facilitate the exchange of information and communication, however, as mentioned, such efforts have been slow going and progress has been minimal as it relates to the completion of an audit. The Company cannot estimate with any level of certainty how long the audit of Mama Foods Co., Ltd. may take to complete, or if ever it will be completed at all. The Company does not intend to acquire Mama Foods Co., Ltd., under any terms, prior to the completion of its PCAOB audit.

Review, Approval and Ratification of Related Party Transactions

Given our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or ratification of transactions, such as those described above, with our executive officer(s), Director(s) and significant stockholders. We intend to establish formal policies and procedures in the future, once we have sufficient resources and have appointed additional Directors, so that such transactions will be subject to the review, approval or ratification of our Board of Directors, or an appropriate committee thereof. On a moving forward basis, our Directors will continue to approve any related party transaction.

Item 14. Principal Accounting Fees and Services.

Below is the approximate, aggregate amount of fees billed for professional services rendered by our principal accountants with respect to our last two fiscal years.

		2022	2021
Audit fees	BF Borgers CPA PC	$5,500	$3,250
Audit related fees (including reviews)		3,000	-
Tax fees		-	-
All other fees		-	-
Total		$8,500	$3,250

Services rendered by our principal accountants with respect to our last two fiscal year ends, each having ended March 31^st.

		2023	2022
Audit fees	BF Borgers CPA PC	$-	$13,250
Audit related fees	BF Borgers CPA PC	$-	$-
Audit fees	M&K CPAS, PLLC	$15,000	$-
Audit related fees	M&K CPAS, PLLC	$-	$-
Tax fees		-	-
All other fees		-	-

Total		$15,000	$13,250

Audit fees represent the professional services rendered for the audit of our annual financial statements and the review of our financial statements included in quarterly reports, along with services normally provided by the accounting firm in connection with statutory and regulatory filings or engagements. Audit-related fees represent professional services rendered for assurance and related services by the accounting firm that are reasonably related to the performance of the audit or review of our financial statements that are not reported under audit fees.

Tax fees represent professional services rendered by the accounting firm for tax compliance, tax advice, and tax planning. All other fees represent fees billed for products and services provided by the accounting firm, other than the services reported for in the other categories.

- 12 -

Table of Contents

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a) Financial Statements

1. Financial statements for our company are listed in the index under Item 8 of this document

2. All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

(b) Exhibits required by Item 601 of Regulation S-K.

Exhibit No.		Description
3.1		Certificate of Incorporation (1)
3.11		Certificate of Amendment (2)
3.12		Certificate of Amendment (3)
3.2		By-laws (1)
31		Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-K for the year ended March 31, ~~2022~~2023 (4)
32		Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (4)
101.INS		XBRL Instance Document (5)
101.SCH		XBRL Taxonomy Extension Schema (5)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase (5)
101.DEF		XBRL Taxonomy Extension Definition Linkbase (5)
101.LAB		XBRL Taxonomy Extension Label Linkbase (5)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase (5)

(1)	Filed as an exhibit to the Company's Form 10-12G, as filed with the SEC on May 3, 2021, and incorporated herein by this reference.
(2)	Filed as an exhibit to the Company's Form 8-K, as filed with the SEC on August 25, 2021, and incorporated herein by this reference.
(3)	Filed as an exhibit to the Company's Form 8-K, as filed with the SEC on February 23, 2022, and incorporated herein by this reference.
(4)	Filed herewith.
(5)	Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Annual Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dr. Foods, Inc.

(Registrant)

By: /s/ Koichi Ishizuka

Koichi Ishizuka, Chief Executive Officer, Chief Financial Officer, Director

Dated: ~~June~~August 1316, ~~2022~~2023

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Koichi Ishizuka

Koichi Ishizuka, Chief Executive Officer, Chief Financial Officer, Director

Dated: ~~June~~August 1316, ~~2022~~2023

- 13 -

Filing Compare · Japan Food Tech Holdings, Inc.